Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTASEL1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:49:15 ON 13 JUL 2007

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:49:27 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6
DICTIONARY FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10509268g.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-11

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:49:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23560 TO ITERATE

8.5% PROCESSED 2000 ITERATIONS 14 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 462015 TO 480385
PROJECTED ANSWERS: 2528 TO 4068

L2 14 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:49:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 475344 TO ITERATE

100.0% PROCESSED 475344 ITERATIONS 2050 ANSWERS
SEARCH TIME: 00.00.05

L3 2050 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 09:49:53 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 12 Jul 2007 (20070712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 336 L3

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.47 172.78

FILE 'REGISTRY' ENTERED AT 09:49:58 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6
DICTIONARY FILE UPDATES: 12 JUL 2007 HIGHEST RN 942260-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10509268h.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-11
ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 9-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 09:50:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23560 TO ITERATE

8.5% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 462015 TO 480385
PROJECTED ANSWERS: 531 TO 1353

L6 4 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 09:51:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 475344 TO ITERATE

100.0% PROCESSED 475344 ITERATIONS 623 ANSWERS
SEARCH TIME: 00.00.04

L7 623 SEA SSS FUL L5

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	345.33

FILE 'CAPLUS' ENTERED AT 09:51:07 ON 13 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 12 Jul 2007 (20070712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7
L8 30 L7

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 158.10 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L8 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1350295 CAPLUS
DOCUMENT NUMBER: 144:88168
TITLE: Preparation of indol-2-ol compounds containing heterocycle moiety as kinase inhibitors
INVENTOR(S): Bressi, Jerome C.; Gangloff, Anthony R.; Hosfield, David J.; Jennings, Andrew John; Paraselli, Bheema R.; Stafford, Jeffrey Alan
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123672	A2	20051229	WO 2005-US20890	20050613
WO 2005123672	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1773807	A2	20070418	EP 2005-763319	20050613
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-579787P P 20040614
WO 2005-US20890 W 20050613
OTHER SOURCE(S): CASREACT 144:88168; MARPAT 144:88168
GI

L8 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I, II [J, K, L, Y = C, N; M = CH, N; X, Z = C, N, O, etc.; R3, R4, R5 = H, halo, amino, etc.; R3 and R4, or R4 and R5 are taken together to form (un)substituted ring, with the proviso that R3, R4 and/or are absent when J,K and/or L resp. are nitrogen; R7 = H, substituent convertible in vivo to H; R13, R14 = H, alkyl, alkoxy, etc.; R16, R17 = H, alkyl, heterocycloalkyl, etc.; further details on X, Y, Z are given.] and their pharmaceutically acceptable salts were prepared For instance, general procedure is provided for the preparation of 3-(2-amino-6-methylpyrimidin-4-yl)-1H-indol-2-ol (III). In AIK (aurora-A kinase) inhibition assays, exemplified compound III exhibited the IC50 value of <100,000 nM. Compds. I and II are claimed useful for the treatment of inflammation, cancer, etc.

IT 872174-41-9P 872174-42-0P 872174-43-1P
872174-44-2P 872174-45-3P 872174-46-4P
872174-47-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indol-2-ol compds. containing heterocycle moiety as kinase inhibitors for treatment of inflammation, cancer, etc.)

RN 872174-41-9 CAPLUS
CN 1H-Indol-2-ol, 3-(2-amino-6-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 872174-42-0 CAPLUS
CN 1H-Indol-2-ol, 3-(3-amino-1-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 872174-43-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-(3-amino-1-isoquinolinyl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 872174-44-2 CAPLUS
CN 6H-Pyrrolo[2,3-g]benzothiazol-7-ol, 8-(3-amino-1-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 872174-45-3 CAPLUS
CN Ethanesulfonamide, N-[3-(3-amino-1-isoquinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 872174-46-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1,7-dihydro-7-oxo-1,8-naphthyridin-2-yl)-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 872174-47-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1,7-dihydro-7-oxo-1,8-naphthyridin-2-yl)-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



IT 872174-48-6 872174-49-7 872174-50-0
872174-51-1 872174-52-2 872174-53-3
872174-54-4 872174-55-5 872174-56-6
872174-57-7 872174-58-8 872174-59-9
872174-60-2 872174-61-3 872174-62-4
872320-89-3 872320-90-6 872320-91-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of indol-2-ol compds. containing heterocycle moiety as kinase inhibitors for treatment of inflammation, cancer, etc.)

RN 872174-48-6 CAPLUS
CN Methanesulfonamide, N-[2-hydroxy-3-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 872174-49-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-N-methyl-3-(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-50-0 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-imidazo[4,5-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 872174-51-1 CAPLUS
CN 1H-Indol-2-ol, 5-fluoro-3-(1H-imidazo[4,5-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 872174-52-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-(1H-imidazo[4,5-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 872174-53-3 CAPLUS
CN Methanesulfonamide, N-[2-hydroxy-3-(1H-imidazo[4,5-b]pyridin-5-yl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 872174-58-8 CAPLUS
CN Methanesulfonamide, N-[2-hydroxy-3-(1H-pyrazolo[3,4-b]pyridin-6-yl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 872174-59-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-N-methyl-3-(1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-60-2 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-61-3 CAPLUS
CN 1H-Indol-2-ol, 5-fluoro-3-(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-54-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-3-(1H-imidazo[4,5-b]pyridin-5-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 872174-55-5 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-56-6 CAPLUS
CN 1H-Indol-2-ol, 5-fluoro-3-(1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-57-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-(1H-pyrazolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872174-62-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 872320-89-3 CAPLUS
CN 1H-Indole-5-carboximidamide, N',2-dihydroxy-3-(1H-pyrrolo[2,3-b]pyridin-6-yl)-, [C(Z)]- (9CI) (CA INDEX NAME)



RN 872320-90-6 CAPLUS
CN 1H-Indole-5-carboximidamide, N',2-dihydroxy-3-(1H-imidazo[4,5-b]pyridin-5-yl)-, [C(Z)]- (9CI) (CA INDEX NAME)



RN 872320-91-7 CAPLUS
CN 1H-Indole-5-carboximidamide, N',2-dihydroxy-3-(1H-pyrazolo[3,4-b]pyridin-6-yl)-, [C(Z)]- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1200990 CAPLUS
DOCUMENT NUMBER: 143:460026
TITLE: Preparation of hydroxyindole derivatives as kinase inhibitors
INVENTOR(S): Bressi, Jerome C.; Gangloff, Anthony R.; Hosfield, David J.; Jennings, Andrew John; Paraselli, Bheema R.; Stafford, Jeffrey Alan
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105788	A1	20051110	WO 2005-US13410	20050420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005250829	A1	20051110	US 2005-111479	20050420
EP 1763524	A1	20070321	EP 2005-737696	20050420
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-565236P	P 20040423
			WO 2005-US13410	W 20050420
OTHER SOURCE(S):	MARPAT 143:460026			

GI



I

AB Title compds. I [R3-5 = H, halo, amino, etc.; R6 = H, alkyl with the proviso the R6 = absent when M = N; R7 = H or a substituent convertible in vivo to H; R11-13 = H, alkyl, alkoxy, mercapto, etc.; J, K, L, M = C, N; Q, V = C, N, O, S with the proviso that Q and V are not O or S when that atom is part of a double bond; U = C, N with multiple provisions] are prepared For instance, general procedures are provided for the preparation of

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

3-(1H-benzimidazol-2-yl)-1H-indol-2-ol. I are kinase inhibitors [no data] and are useful for the treatment of cancer.

IT 868837-97-2P 868837-98-3P 868837-99-4P
868838-00-0P 868838-01-1P 868838-02-2P
868838-03-3P 868838-04-4P 868838-05-5P
868838-06-6P 868838-07-7P 868838-08-8P
868838-09-9P 868838-10-2P 868838-11-3P
868838-12-4P 868838-13-5P 868838-14-6P
868838-15-7P 868838-16-8P 868838-17-9P
868838-18-0P 868838-19-1P 868838-20-4P
868838-21-5P 868838-22-6P 868838-23-7P
868838-24-8P 868838-25-9P 868838-26-0P
868838-27-1P 868838-28-2P 868838-29-3P
868838-30-6P 868838-31-7P 868838-32-8P
868838-33-9P 868838-34-0P 868838-35-1P
868838-36-2P 868838-37-3P 868838-38-4P
868838-39-5P 868838-40-8P 868838-41-9P
868838-42-0P 868838-43-1P 868838-44-2P
868838-45-3P 868838-46-4P 868838-47-5P
868838-48-6P 868838-49-7P 868838-50-0P
868838-51-1P 868838-52-2P 868838-53-3P
868838-54-4P 868838-55-5P 868838-56-6P
868838-57-7P 868838-58-8P 868838-59-9P
868838-60-2P 868838-61-3P 868838-62-4P
868838-63-5P 868838-64-6P 868838-65-7P
868838-66-8P 868838-67-9P 868838-68-0P
868838-69-1P 868838-70-4P 868838-71-5P
868838-72-6P 868838-73-7P 868838-74-8P
868838-75-9P 868838-76-0P 868838-77-1P
868838-78-2P 868838-79-3P 868838-80-6P
868838-81-7P, 3-(1-Methyl-1H-benzimidazol-2-yl)-1H-indol-2-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyindole derivs. as kinase inhibitors)

RN 868837-97-2 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 868837-98-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[3-(dimethylamino)propyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868837-99-4 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(dimethylamino)ethyl]amino]-1H-benzimidazol-2-yl]-

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(9CI) (CA INDEX NAME)



RN 868838-00-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[2-(dimethylamino)ethoxy]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-01-1 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(dimethylamino)ethyl]thio]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-02-2 CAPLUS
CN 1-Propanone, 3-(dimethylamino)-1-[2-(2-hydroxy-1H-indol-3-yl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-03-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[3-(4-morpholinyl)propyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 868838-04-4 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-05-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-06-6 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(4-morpholinyl)ethyl]thio]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-07-7 CAPLUS
CN 1-Propanone, 1-[2-(2-hydroxy-1H-indol-3-yl)-1H-benzimidazol-5-yl]-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 868838-08-8 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-fluoro- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 868838-09-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-(1H-benzimidazol-2-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-10-2 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-(1H-benzimidazol-2-yl)-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 868838-11-3 CAPLUS
CN Methanesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-12-4 CAPLUS
CN Ethanesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 868838-13-5 CAPLUS
CN Benzenesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-14-6 CAPLUS
CN 3-Pyridinesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-15-7 CAPLUS
CN Benzenemethanesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-16-8 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-(1H-benzimidazol-2-yl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 868838-17-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1H-benzimidazol-2-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-18-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1H-benzimidazol-2-yl)-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 868838-19-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1H-benzimidazol-2-yl)-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-20-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1H-benzimidazol-2-yl)-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 868838-21-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(1H-benzimidazol-2-yl)-2-hydroxy-N-2-thienyl- (9CI) (CA INDEX NAME)



RN 868838-22-6 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-23-7 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-24-8 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-25-9 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-(3-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-26-0 CAPLUS
CN 1H-Indol-2-ol, 3-(1H-benzimidazol-2-yl)-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 868838-27-1 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 868838-28-2 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 868838-29-3 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-(2-benzoxazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-30-6 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-(2-benzoxazolyl)-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 868838-31-7 CAPLUS
CN Methanesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-32-8 CAPLUS
CN Ethanesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-33-9 CAPLUS
CN Benzenesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-34-0 CAPLUS
CN 3-Pyridinesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-35-1 CAPLUS
CN Benzenemethanesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-36-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-(2-benzoxazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-37-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-38-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 868838-39-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-40-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 868838-41-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-2-hydroxy-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 868838-46-4 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-(3-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-47-5 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 868838-48-6 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 868838-49-7 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 868838-50-0 CAPLUS



RN 868838-42-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzoxazolyl)-2-hydroxy-N-2-thienyl- (9CI) (CA INDEX NAME)



RN 868838-43-1 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-44-2 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-45-3 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzoxazolyl)-5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

CN 1H-Indole-5-carbonitrile, 3-(2-benzothiazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-51-1 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-(2-benzothiazolyl)-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 868838-52-2 CAPLUS
CN Methanesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-53-3 CAPLUS
CN Ethanesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-54-4 CAPLUS
CN Benzenesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-55-5 CAPLUS
CN 3-Pyridinesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-56-6 CAPLUS
CN Benzenemethanesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-57-7 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-(2-benzothiazolyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-58-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-59-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 868838-60-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-61-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 868838-62-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-2-hydroxy-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 868838-63-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzothiazolyl)-2-hydroxy-N-2-thienyl- (9CI) (CA INDEX NAME)



RN 868838-64-6 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-65-7 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-66-8 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-67-9 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-(3-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 868838-68-0 CAPLUS
CN 1H-Indol-2-ol, 3-(2-benzothiazolyl)-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 868838-69-1 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[3-(dimethylamino)propyl]-1H-imidazo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-70-4 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[3-(4-morpholinyl)propyl]-1H-imidazo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 868838-71-5 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[[2-(dimethylamino)ethyl]amino]oxazolo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-72-6 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[[2-(4-morpholinyl)ethyl]amino]oxazolo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-73-7 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[2-(dimethylamino)ethoxy]thiazolo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-74-8 CAPLUS
CN 1H-Indol-2-ol, 3-[6-[2-(4-morpholinyl)ethoxy]thiazolo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 868838-80-6 CAPLUS
CN Methanesulfonamide, N-[2-hydroxy-3-[6-[3-(4-morpholinyl)propyl]oxazolo[4,5-b]pyridin-2-yl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 868838-81-7 CAPLUS
CN 1H-Indol-2-ol, 3-(1-methyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 868838-75-9 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(dimethylamino)ethyl]thio]-1H-imidazo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-76-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[[2-(4-morpholinyl)ethyl]thio]-1H-imidazo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-77-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[3-(dimethylamino)-1-oxopropyl]-1H-benzimidazol-2-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 868838-78-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[3-(4-morpholinyl)-1-oxopropyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 868838-79-3 CAPLUS
CN Methanesulfonamide, N-[3-[6-[3-(dimethylamino)propyl]oxazolo[4,5-b]pyridin-2-yl]-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588997 CAPLUS
DOCUMENT NUMBER: 143:115438
TITLE: Preparation of substituted indol-2-ols as kinase inhibitors
INVENTOR(S): Gangloff, Anthony R.; Nowakowski, Jacek; Paraselli, Bheema R.; Stafford, Jeffrey A.; Tennant, Michael G.
PATENT ASSIGNEE(S): Syrrx, Inc., USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061519	A1	20050707	WO 2004-US42631	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005153966	A1	20050714	US 2004-15348	20041217
EP 1694686	A1	20060830	EP 2004-814774	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007514759	T	20070607	JP 2006-545517	20041217
PRIORITY APPLN. INFO.:			US 2003-531202P	P 20031219
			WO 2004-US42631	W 20041217

OTHER SOURCE(S): MARPAT 143:115438
GI



AB The invention relates to compds. I [R3-R6 = H, halo, perhaloalkyl, etc.; or two of R3-R6 are taken together to form a ring, with the proviso that R3-R6 are absent where the ring atom to which R3-R6 are bound is nitrogen;

L8 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
R7 = H or a substituent convertible in vivo to hydrogen; R11-R14 = H, alkyl, alkoxy, etc.; or any two of R11-R14 are taken together to form a ring, with the proviso that R11-R14 are absent when the ring atom to which R11-R14 are bound is nitrogen; A, B, U and V = C, N; J, K, L and M = C, N; W = CR21, N; X = CR15, N; R15 = H, NO2, CN, etc.; R21 = H, NO2, CN, etc.; with the proviso that at least one of R3-R6 is selected from NH2, furanyl, quinolinyl, indolyl, pyridinyl, carboxamidinyl, aminosulfonyl, and arylalkyl (each unsubstituted or substituted), or a substituted sulfonamidyl when A, B, U, V and W are all C; or X = CR15 and R15 is an N-linked moiety when A, B, U, V and W are all C; or X = CR15 and R15 is an S-linked moiety when A, B, U, V and W are all C] that may be used to inhibit kinases, as well as compns. of matter and kits comprising these compds. General procedures for synthesis of compds. I are provided. Over 150 compds. I such as II were prepd. and characterized. The exemplified compds. I have been found to have IC50 values in the range of about 0.001 to about 100,000 nM. Other values for IC50 are in the range of about 0.001 to about 10,000 nM for AIK and/or c-KIT. The present invention also relates to methods for inhibiting kinases, as well as treatment methods using compds. I.

IT 857258-00-5P 857258-01-6P 857258-04-9P
857258-05-0P 857258-06-1P 857258-07-2P
857258-08-3P 857258-09-4P 857258-10-7P
857258-11-8P 857258-12-9P 857258-13-0P
857258-14-1P 857258-15-2P 857258-16-3P
857258-17-4P 857258-18-5P 857258-19-6P
857258-20-9P 857258-21-0P 857258-22-1P
857258-23-2P 857258-24-3P 857258-25-4P
857258-26-5P 857258-27-6P 857258-28-7P
857258-29-8P 857258-30-1P 857258-31-2P
857258-32-3P 857258-33-4P 857258-34-5P
857258-35-6P 857258-36-7P 857258-37-8P
857258-38-9P 857258-39-0P 857258-40-3P
857258-41-4P 857258-42-5P 857258-43-6P
857258-44-7P 857258-45-8P 857258-46-9P
857258-47-0P 857258-48-1P 857258-49-2P
857258-50-5P 857258-51-6P 857258-52-7P
857258-53-8P 857258-54-9P 857258-55-0P
857258-56-1P 857258-57-2P 857258-58-3P
857258-59-4P 857258-60-7P 857258-61-8P
857258-62-9P 857258-63-0P 857258-64-1P
857258-65-2P 857258-66-3P 857258-67-4P
857258-68-5P 857258-69-6P 857258-70-9P
857258-71-0P 857258-72-1P 857258-74-3P
857258-75-4P 857258-76-5P 857258-77-6P
857258-78-7P 857258-79-8P 857258-81-2P
857258-82-3P 857258-83-4P 857258-84-5P
857258-85-6P 857258-86-7P 857258-87-8P
857258-88-9P 857258-89-0P 857258-90-3P
857258-91-4P 857258-92-5P 857258-93-6P
857258-94-7P 857258-95-8P 857258-96-9P
857258-97-0P 857258-98-1P 857258-99-2P
857259-00-8P 857259-01-9P 857259-02-0P
857259-03-1P 857259-04-2P 857259-05-3P
857259-06-4P 857259-07-5P 857259-08-6P
857259-09-7P 857259-10-0P 857259-11-1P
857259-12-2P 857259-13-3P 857259-14-4P
857259-15-5P 857259-16-6P 857259-17-7P
857259-18-8P 857259-19-9P 857259-20-2P
857259-21-3P 857259-22-4P 857259-23-5P
857259-24-6P 857259-25-7P 857259-26-8P

L8 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
857259-27-9P 857259-28-0P 857259-29-1P
857259-30-4P 857259-31-5P 857259-32-6P
857259-33-7P 857259-34-8P 857259-35-9P
857259-36-0P 857259-37-1P 857259-38-2P
857259-39-3P 857259-40-6P 857259-41-7P
857259-42-8P 857259-43-9P 857259-44-0P
857259-45-1P 857259-46-2P 857259-47-3P
857259-48-4P 857259-49-5P 857259-50-8P
857259-51-9P 857259-52-0P 857259-54-2P
857259-55-3P 857259-56-4P 857259-57-5P
857259-58-6P 857259-59-7P 857259-60-0P
857259-61-1P 857259-62-2P 857259-63-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted indol-2-ols as Aurora-2 and c-KIT inhibitors)

RN 857258-00-5 CAPLUS
CN 1H-Indol-2-ol, 3-(2-quinoxalinyl)- (9CI) (CA INDEX NAME)



RN 857258-01-6 CAPLUS
CN 1H-Indol-2-ol, 5-amino-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-04-9 CAPLUS
CN 1H-Indol-2-ol, 5-(3-fluorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-05-0 CAPLUS
CN 1H-Indol-2-ol, 5-[1,1'-biphenyl]-4-yl-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 857258-06-1 CAPLUS
CN 1H-Indol-2-ol, 5-(4-methylphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-07-2 CAPLUS
CN 1H-Indol-2-ol, 5-(4-phenoxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-08-3 CAPLUS
CN 1H-Indol-2-ol, 5-(4-fluorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-09-4 CAPLUS
CN 1H-Indol-2-ol, 5-(4-methoxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-10-7 CAPLUS

L8 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Indol-2-ol, 5-[4-(methylsulfonyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-11-8 CAPLUS
CN Benzonitrile, 4-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-12-9 CAPLUS
CN 1H-Indol-2-ol, 5-(2-phenylethenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-13-0 CAPLUS
CN 1H-Indol-2-ol, 5-[4-(hydroxymethyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-14-1 CAPLUS
CN 1H-Indol-2-ol, 5-(4-hydroxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-15-2 CAPLUS
CN 1H-Indol-2-ol, 5-[2-(4-fluorophenyl)ethenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-16-3 CAPLUS
CN 1H-Indol-2-ol, 5-(3-aminophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-17-4 CAPLUS
CN 1H-Indol-2-ol, 5-(3-furanyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-18-5 CAPLUS
CN 1H-Indol-2-ol, 5-(2-fluorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-19-6 CAPLUS
CN 1H-Indol-2-ol, 5-(2-methoxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX



RN 857258-24-3 CAPLUS
CN 1H-Indol-2-ol, 5-(2-chlorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-25-4 CAPLUS
CN 1H-Indol-2-ol, 6-(4-fluorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-26-5 CAPLUS
CN 1H-Indol-2-ol, 6-phenyl-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-27-6 CAPLUS
CN 1H-Indol-2-ol, 6-[3-(methylsulfonyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-28-7 CAPLUS

NAME)



RN 857258-20-9 CAPLUS
CN 1H-Indol-2-ol, 3-(2-quinolinyl)-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 857258-21-0 CAPLUS
CN 1H-Indol-2-ol, 5-(2-hydroxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-22-1 CAPLUS
CN 1H-Indol-2-ol, 6-(2-fluorophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-23-2 CAPLUS
CN 1H-Indol-2-ol, 6-(3-aminophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)

CN Methanesulfonamide, N-[3-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-29-8 CAPLUS
CN Acetamide, N-[3-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-30-1 CAPLUS
CN 1H-Indol-2-ol, 5-[2-(hydroxymethyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-31-2 CAPLUS
CN 1H-Indol-2-ol, 5-(4-aminophenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-32-3 CAPLUS
CN Carbamic acid, [4-(2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 857258-33-4 CAPLUS
CN 1H-Indol-2-ol, 5-(3-ethoxyphenyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-34-5 CAPLUS
CN 1H-Indol-2-ol, 5-[3-(ethylsulfonyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-35-6 CAPLUS
CN 2,5'-Bi-1H-indole, 2'-hydroxy-1-(phenylsulfonyl)-3'-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-36-7 CAPLUS
CN Benzoic acid, 3-amino-5-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-37-8 CAPLUS
CN 1H-Indol-2-ol, 5-(1H-pyrrol-2-yl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-38-9 CAPLUS
CN [2,5'-Bi-1H-indol]-2'-ol, 3'-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-39-0 CAPLUS
CN 1H-Indol-2-ol, 5-(4-pyridinyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-40-3 CAPLUS
CN 1H-Indol-2-ol, 5-[3-(aminomethyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-41-4 CAPLUS
CN 1H-Indol-2-ol, 5-[3-(hydroxymethyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-42-5 CAPLUS
CN 1H-Indol-2-ol, 5-[4-(aminomethyl)phenyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-43-6 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(2-phenylethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-44-7 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(1-piperidinylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-45-8 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(phenylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-46-9 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[[2-(diethylamino)ethyl]amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-47-0 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(phenylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-48-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[[2-(1-piperazinyl)ethyl]amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-49-2 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(methylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-50-5 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(ethylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-51-6 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(diethylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-52-7 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(1-methylethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-53-8 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(cyclohexylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-54-9 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(cyclopentylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-55-0 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(dimethylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-56-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(1,1-dimethylethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-57-2 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(methylphenylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-58-3 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(4-morpholinyl)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-59-4 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(4-methyl-1-piperazinyl)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-60-7 CAPLUS
CN 1H-Indol-2-ol, 3-[4-([1,1'-biphenyl]-4-ylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-61-8 CAPLUS

CN 1H-Indol-2-ol, 3-[4-[[2-(4-hydroxyphenyl)ethyl]amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-62-9 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[[3-(4-morpholinyl)propyl]amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-63-0 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(4-phenoxyphenyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-67-4 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(3-pyridinylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-68-5 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[[2-(4-morpholinyl)ethyl]amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-69-6 CAPLUS



RN 857258-64-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(methyl-3-pyridinylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-65-2 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(methyl-4-pyridinylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-66-3 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3-fluorophenyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)

CN 1H-Indol-2-ol, 3-[4-(phenylthio)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-70-9 CAPLUS
CN Acetamide, N-[4-[[2-(2-hydroxy-1H-indol-3-yl)-4-quinolinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-71-0 CAPLUS
CN 1H-Indol-2-ol, 3-(4-amino-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-72-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(ethylthio)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-74-3 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(4-aminophenyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-75-4 CAPLUS
CN Acetamide, N-[4-[[2-(2-hydroxy-1H-indol-3-yl)-4-quinolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-76-5 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(6-amino-3-pyridinyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)

RN 857258-81-2 CAPLUS
CN Ethanesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-82-3 CAPLUS
CN Ethanesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-83-4 CAPLUS
CN 1H-Indole-5-carboximidic acid, 2-hydroxy-3-(2-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 857258-84-5 CAPLUS
CN 1H-Indole-5-carboximidamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-85-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[4-(phenylamino)-2-quinolinyl]-



RN 857258-77-6 CAPLUS
CN Acetamide, N-[4-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-78-7 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-79-8 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



(9CI) (CA INDEX NAME)



RN 857258-86-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[4-[(4-aminophenyl)amino]-2-quinolinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 857258-87-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[4-[(2-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-88-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[4-[(3-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-89-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[4-[(4-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857258-90-3 CAPLUS
CN 1H-Indole-5-carboximidamide, N-[3-(dimethylamino)propyl]-2-hydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-91-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[4-[(6-amino-3-pyridinyl)amino]-2-quinolinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 857258-92-5 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(6-amino-3-pyridinyl)amino]-2-quinolinyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 857258-93-6 CAPLUS
CN Ethanesulfonamide, N-[3-[4-[(4-aminophenyl)amino]-2-quinolinyl]-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-94-7 CAPLUS
CN Methanesulfonamide, N-[4-[2-hydroxy-3-(3-methyl-2-quinolinyl)-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-95-8 CAPLUS
CN Methanesulfonamide, N-[3-[2-hydroxy-3-(3-methyl-2-quinolinyl)-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857258-96-9 CAPLUS
CN Ethanesulfonamide, N-[2-hydroxy-3-[4-[(2-pyridinylmethyl)amino]-2-quinolinyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857258-97-0 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-methyl-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-98-1 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-(3-methyl-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857258-99-2 CAPLUS
CN Acetamide, N-[4-[[2-(5-cyano-2-hydroxy-1H-indol-3-yl)-4-quinolinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



RN 857259-00-8 CAPLUS
CN Acetamide, N-[4-[[2-(5-cyano-2-hydroxy-1H-indol-3-yl)-4-quinolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 857259-01-9 CAPLUS
CN Ethanesulfonamide, N-[2-hydroxy-3-[4-[(3-pyridinylmethyl)amino]-2-quinolinyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-02-0 CAPLUS

CN Ethanesulfonamide, N-[2-hydroxy-3-[4-[(4-pyridinylmethyl)amino]-2-quinolinyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-03-1 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-[2-(4-morpholinyl)ethyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-04-2 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-[3-(4-morpholinyl)propyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-05-3 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-3-(2-quinolinyl)-N-[2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 857259-06-4 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-[2-(1-piperidinyl)ethyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-07-5 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-[3-(4-methyl-1-piperazinyl)propyl]-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-08-6 CAPLUS
CN 1H-Indole-5-carboximidamide, 2-hydroxy-N-(4-pyridinylmethyl)-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-09-7 CAPLUS
CN 1H-Indole-5-sulfonamide, N-ethyl-2-hydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-10-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-N-3-pyridinyl-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-11-1 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-[4-[(3-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-12-2 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-[4-[(4-aminophenyl)amino]-2-quinolinyl]-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 857259-13-3 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-[4-[(2-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-14-4 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-[4-[(4-pyridinylmethyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-15-5 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-[4-[(6-amino-3-pyridinyl)amino]-2-quinolinyl]-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 857259-16-6 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-[6-[2-(diethylamino)ethoxy]-2-quinolinyl]-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 857259-17-7 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-[6-[2-(4-morpholinyl)ethoxy]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-18-8 CAPLUS
CN Benzenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-19-9 CAPLUS
CN Benzenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)



RN 857259-20-2 CAPLUS
CN Benzenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-4-nitro- (9CI) (CA INDEX NAME)



RN 857259-21-3 CAPLUS
CN 1-Naphthalenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-22-4 CAPLUS
CN Benzenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 857259-23-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-24-6 CAPLUS
CN 1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-25-7 CAPLUS
CN 2-Thiophenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-26-8 CAPLUS
CN Benzenesulfonamide, N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 857259-27-9 CAPLUS
CN Benzenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-28-0 CAPLUS
CN Benzenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)



RN 857259-29-1 CAPLUS
CN Benzenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]-4-nitro- (9CI) (CA INDEX NAME)



RN 857259-30-4 CAPLUS
CN 1-Naphthalenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-31-5 CAPLUS
CN Benzenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 857259-32-6 CAPLUS
CN 2-Naphthalenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-



RN 857259-37-1 CAPLUS
CN Benzenesulfonamide, 3-chloro-N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-(9CI) (CA INDEX NAME)



RN 857259-38-2 CAPLUS
CN Benzenemethanesulfonamide, 3-chloro-N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-39-3 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-(9CI) (CA INDEX NAME)



RN 857259-40-6 CAPLUS
CN Benzenesulfonamide, 4-amino-N-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]-(9CI) (CA INDEX NAME)

5-yl]- (9CI) (CA INDEX NAME)



RN 857259-33-7 CAPLUS
CN 1,4-Benzodioxin-6-sulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 857259-34-8 CAPLUS
CN Benzenesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 857259-35-9 CAPLUS
CN Benzenemethanesulfonamide, 3-chloro-N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-36-0 CAPLUS
CN Benzenesulfonamide, 3-chloro-N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-41-7 CAPLUS
CN Benzenemethanesulfonamide, N-[3-(4-chloro-2-quinolinyl)-2-hydroxy-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 857259-42-8 CAPLUS
CN 1H-Indole-5-sulfonamide, N,2-dihydroxy-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-43-9 CAPLUS
CN 1H-Indole-5-carboximidamide, N-(acetyloxy)-2-hydroxy-3-(2-quinolinyl)-(9CI) (CA INDEX NAME)



RN 857259-44-0 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(hydroxyamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-45-1 CAPLUS
CN 1H-Indole-5-sulfonamide, N-ethyl-2-hydroxy-3-(6-phenanthridinyl)- (9CI) (CA INDEX NAME)



RN 857259-46-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[6-[2-(diethylamino)ethoxy]-2-quinolinyl]-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



RN 857259-47-3 CAPLUS
CN 1H-Indole-5-carboximidamide, N,2-dihydroxy-3-[4-(phenylamino)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-48-4 CAPLUS
CN Acetamide, N-[5-[[[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]sulfonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857259-54-2 CAPLUS
CN Butanamide, 4-(dimethylamino)-N-[6-(2-hydroxy-1H-indol-3-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857259-55-3 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[6-(2-hydroxy-1H-indol-3-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857259-56-4 CAPLUS
CN 1H-Indol-2-ol, 3-[4-(1-piperidinyl)-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-57-5 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-(2-quinolinyl)-1H-indol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 857259-49-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[6-[2-(diethylamino)ethoxy]-2-quinolinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 857259-50-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[6-[2-(dimethylamino)ethoxy]-2-quinolinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 857259-51-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[6-[2-(dimethylamino)ethoxy]-2-quinolinyl]-N-ethyl-2-hydroxy- (9CI) (CA INDEX NAME)



RN 857259-52-0 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-[6-[2-(dimethylamino)ethoxy]-2-quinolinyl]-N,2-dihydroxy- (9CI) (CA INDEX NAME)



RN 857259-58-6 CAPLUS
CN 3,5'-Bi-1H-indole, 2'-hydroxy-1-(phenylsulfonyl)-3'-(2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-59-7 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-(5-chloro-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-60-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[(2-hydroxyphenyl)amino]-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 857259-61-1 CAPLUS
CN 6H-Pyrrolo[2,3-g]benzothiazol-7-ol, 8-(2-quinolinyl)- (9CI) (CA INDEX

NAME)



RN 857259-62-2 CAPLUS
CN 1H-Indol-2-ol, 3-(4-phenoxy-2-quinolinyl)- (9CI) (CA INDEX NAME)



RN 857259-63-3 CAPLUS
CN Urea, N-(4-fluoro-3-nitrophenyl)-N'-[2-(2-hydroxy-1H-indol-3-yl)-5-quinolinyl]- (9CI) (CA INDEX NAME)



IT 857259-53-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted indol-2-ols as Aurora-2 and c-KIT inhibitors)
RN 857259-53-1 CAPLUS
CN 1H-Indol-2-ol, 3-(5-chloro-2-quinolinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:283287 CAPLUS
DOCUMENT NUMBER: 142:336240
TITLE: Preparation of heterocyclic-substituted indoles as inhibitors of GSK3β
INVENTOR(S): Berg, Stefan; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027823	A2	20050331	WO 2004-SE1363	20040921
WO 2005027823	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273771	A1	20050331	AU 2004-273771	20040921
CA 2538381	A1	20050331	CA 2004-2538381	20040921
EP 1667990	A2	20060614	EP 2004-775465	20040921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014632	A	20061107	BR 2004-14632	20040921
CN 1886397	A	20061227	CN 2004-80034700	20040921
JP 2007506734	T	20070322	JP 2006-527944	20040921
PRIORITY APPLN. INFO.:			SE 2003-2546 A	20030924
			WO 2004-SE1363 W	20040921

OTHER SOURCE(S): CASREACT 142:336240; MARPAT 142:336240
GI



AB Title compds. I [P = 5-6-membered heteroarom. ring; R1 = H; R2 = alkyl, CN, halo, etc.; R3 = alkyl, CN, NO2, carboxy, etc.; m, n = 0-4] and derivs. are prepared For instance, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile is prepared by the reaction of 2-oxoindoline-6-carbonitrile and 1-[(6-chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine (preparation given). Ki of selected compds. of

the invention was 20 μM for GSK3β. I are useful for the treatment of, e.g., Alzheimer's Disease.
IT 698345-96-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 848474-13-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)
RN 698345-96-9 CAPLUS
CN Piperazine, 1-[(6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 848474-13-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 848472-54-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-55-9P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(morpholin-4-yl)ethyl]nicotinamide hydrochloride 848472-56-0P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide hydrochloride 848472-57-1P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 848472-58-2P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride 848472-59-3P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 848472-60-6P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 848472-62-8P, 2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-64-0P, 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848472-66-2P, 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile 848472-68-4P, 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-70-8P, 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-

yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-72-0P, 2-Hydroxy-3-[5-[[4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-74-2P, 2-Hydroxy-3-[5-[[4-(2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-76-4P, 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-78-6P, 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-80-0P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-82-2P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848472-84-4P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-86-6P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848472-88-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848472-90-2P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(thiophen-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848472-92-4P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848472-93-5P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide 848472-95-7P, N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-97-9P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-99-1P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-01-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[4-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-03-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-05-2P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide 848473-07-4P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-09-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide 848473-11-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[4-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-13-2P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-15-4P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide 848473-17-6P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-19-8P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide 848473-21-2P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride 848473-23-4P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide 848473-25-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-27-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide 848473-29-0P, N-Benzyl-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide

hydrochloride 848473-31-4P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride 848473-33-6P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-35-8P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-39-2P, 2-Hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-41-6P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-3-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-43-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-4-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-45-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-47-2P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-49-4P, 2-Hydroxy-N-[2-(methylsulfonyl)ethyl]-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-52-9P, 3-(4-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide 848473-54-1P, 3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-[2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl]-1H-indole-5-carboxamide hydrochloride 848473-56-3P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-58-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-sulfonamide hydrochloride 848473-61-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-63-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carboxamide hydrochloride 848473-64-3P, 3-[5-[[4-[2-(Dimethylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848473-65-4P, 2-Hydroxy-N-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1H-indole-5-carboxamide hydrochloride 848473-66-5P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-67-6P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-69-7P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-69-8P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-70-1P, N-Benzyl-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-71-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride 848473-72-3P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-73-4P, N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-74-5P, 3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride 848473-75-6P, 2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-76-7P, 2-Hydroxy-N-methyl-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-77-8P, 6-Bromo-2-hydroxy-N-methyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-78-9P, 6-Bromo-2-hydroxy-N-isopropyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-79-0P, 6-Bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-

indole-5-carboxamide hydrochloride 848473-80-3P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-81-4P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848473-82-5P, N-[3-(Dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-83-6P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-84-7P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide hydrochloride 848473-85-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide 848473-86-9P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-87-0P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-88-1P, 2-Hydroxy-N-(3-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-89-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-5-carboxamide hydrochloride 848473-90-5P, 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-91-6P, 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-92-7P, N-(Cyanomethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-93-8P, N-(Cyanomethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-94-9P, N-(2-Furylmethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-95-0P, N-(2-Furylmethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-96-1P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-97-2P, 2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-98-3P, 2-Hydroxy-3-[5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-99-4P, 2-Hydroxy-3-[6-(2-(morpholin-4-yl)ethoxy)pyrimidin-4-yl]-1H-indole-6-carbonitrile hydrochloride 848474-00-0P, 3-[6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848474-01-1P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid hydrochloride 848474-02-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-indole-5-carboxamide hydrochloride 848474-03-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848474-04-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-05-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(thiophen-2-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-06-6P, N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-07-7P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-08-8P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-

yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-09-9P, N-(Cyanomethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-10-2P, 2-Hydroxy-3-[5-(4-methylpiperazinesulfon-1-yl)pyridin-2-yl]-1H-indole-5-carboxylic acid N-[(carbamoyl)methyl]amide hydrochloride 848474-11-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(methylsulfonyl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-14-6P 848474-15-7P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid N-[(thiophen-2-yl)methyl]amide 848474-16-8P 848474-17-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid benzylamide 848474-18-0P 848474-19-1P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carboxylic acid [2-(methanesulfonyl)ethyl]amide 848567-90-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848472-54-8 CAPLUS

CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-55-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-56-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-57-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848472-58-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-59-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-66-2 CAPLUS
CN 1-Piperazineethanamine, 4-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 848472-68-4 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-70-8 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)





● HCl

RN 848472-60-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848472-62-8 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-64-0 CAPLUS
CN 1-Piperazineethanamine, 4-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 848472-72-0 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-74-2 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848472-76-4 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-78-6 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 848472-80-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-82-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848472-84-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



● HCl

RN 848472-93-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848472-95-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-97-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-86-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848472-88-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-90-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-92-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 848472-99-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-01-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-03-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-05-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 848473-07-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-09-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 848473-11-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-13-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-



RN 848473-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 848473-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

hydroxy-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-15-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 848473-17-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-19-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



● HCl

RN 848473-27-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 848473-29-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-31-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-33-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-35-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-39-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-41-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-43-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-45-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-47-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-49-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(methylsulfonyl)ethyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-52-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(4-cyano-2-pyridinyl)-2-hydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 848473-54-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(5-cyano-2-pyridinyl)-2-hydroxy-N-[2-[(4-methyl-1-piperazinyl)sulfonyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-56-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-58-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-61-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-63-2 CAPLUS
CN 1H-Indole-6-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-64-3 CAPLUS
CN 1-Piperazineethanamine, 4-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-68-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-69-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-70-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



● HCl

RN 848473-65-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-(5-nitro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-66-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-67-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

RN 848473-71-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-72-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-73-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-74-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(5-cyano-2-pyridinyl)-2-hydroxy-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-75-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-76-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-methyl-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-77-8 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-methyl-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-81-4 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-82-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-[3-(dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-83-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-78-9 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(1-methylethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-79-0 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-80-3 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-84-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-85-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 848473-86-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-87-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-88-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(3-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-89-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-93-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-94-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-95-0 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-96-1 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-



● HCl

RN 848473-90-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-91-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848473-92-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-97-2 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-98-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(3-oxo-1-piperazinyl)methyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-99-4 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-00-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 3-[6-[2-[bis(1-methylethyl)amino]ethoxy]-4-pyrimidinyl]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-01-1 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-02-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-03-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-04-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-05-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-06-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-07-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-08-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-09-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-10-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-amino-2-oxoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 848474-11-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-14-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2-thienylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 848474-15-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 848474-16-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 848474-17-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 848474-18-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-19-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 848567-90-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-amino-3-oxopropyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 848473-37-0, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848473-37-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 848472-43-5P 848472-45-7P, Methyl 2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylate 848472-47-9P, Methyl 3-[5-[(diethylamino)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carboxylate 848472-48-0P, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate hydrochloride 848472-50-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid 848472-53-7P, Methyl 3-(4-cyanopyridin-2-yl)-2-hydroxy-1H-indole-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848472-43-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 848472-45-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 848472-47-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 848472-48-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-50-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-

L8 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
piperazinyl)sulfonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 848472-53-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-(4-cyano-2-pyridinyl)-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 851085-23-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-2,5-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:199862 CAPLUS
DOCUMENT NUMBER: 142:447077
TITLE: The reaction between 3-aminocrotonates and oxindol-3-ylidene derivatives: synthesis of highly substituted pyrroles
AUTHOR(S): Rehn, Stanley; Bergman, Jan
CORPORATE SOURCE: Unit for Organic Chemistry, Department of Biosciences, Karolinska Institute and Soedertoern University College, Huddinge, SE-141 57, Swed.
SOURCE: Tetrahedron (2005), 61(12), 3115-3123
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:447077
AB The reaction between 3-aminocrotonates and 3-acetonylideneoxindole in refluxing toluene resulted in 2-pyrrol-3'-yloxindoles in high yields (around 90%). At room temperature the 2-pyrrol-3'-yloxindoles exists as keto-enol tautomers. Treatment with POCl3 yielded the 2-chloro-3-pyrrolyl indole, which gave the pyrrolo annulated indolopyran-2-one upon basic hydrolysis of 2-chloro-3-pyrrolyl indole Me ester.
IT 851085-22-8P 851085-24-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tautomerism of pyrrolyloxindoles)
RN 851085-22-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-2,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 851085-24-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-1,2,5-trimethyl-, methyl ester (9CI) (CA INDEX NAME)



IT 851085-23-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tautomerism of pyrrolyloxindoles)

L8 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1153537 CAPLUS
DOCUMENT NUMBER: 143:348661
TITLE: Photophysical and spectroscopic studies of indigo derivatives in their keto and leuco forms. [Erratum to document cited in CA141:315830]
AUTHOR(S): Seixas de Melo, J.; Moura, A. P.; Melo, M. J.
CORPORATE SOURCE: Chemistry Department, University of Coimbra, Coimbra, 3004-535, Port.
SOURCE: Journal of Physical Chemistry A (2005), 109(3), 534
CODEN: JPCAFH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In Figure 1, the inset structure for the leuco form of indigo was given incorrectly. The correct structure for the leuco form of indigo, in basic medium, as it is consensually accepted (and mentioned in the text) was clearly established by NMR and deuterium substitution by Voss (2000) and Voss and Schramm (2000).
IT 75038-06-1, Leuco indirubin
RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(photophys. and spectroscopic studies of indigo derivs. in their keto and leuco forms (Erratum))
RN 75038-06-1 CAPLUS
CN [2,3'-Bi-1H-indole]-2',3-diol (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:620427 CAPLUS
DOCUMENT NUMBER: 141:315830
TITLE: Photophysical and spectroscopic studies of indigo derivatives in their keto and leuco forms
AUTHOR(S): Seixas de Melo, J.; Moura, A. P.; Melo, M. J.
CORPORATE SOURCE: Chemistry Department, University of Coimbra, Coimbra, 3004-535, Port.
SOURCE: Journal of Physical Chemistry A (2004), 108(34), 6975-6981
CODEN: JPCAFH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A comprehensive spectroscopic and photophys. study of the keto and leuco forms of indigo and three other ring-substituted derivs. in solution was performed. The characterization involves absorption, fluorescence, and triplet-triplet absorption spectra, making it possible to obtain the quantum yields for fluorescence (ΦF), singlet-triplet intersystem crossing (ΦISC), internal conversion (ΦIC), and lifetimes for fluorescence (τF) and triplet decay (τT). For the case of the keto forms, pulse radiolysis expts. have revealed the existence of a triplet acceptor (from energy transfer from different donors) for the indigo, tyrian purple, and indirubin compds. It is shown that with the keto form the major deactivation pathway involves internal conversion from the lowest singlet excited state to the ground state whereas with the leuco form there is competition between internal conversion, triplet formation, and fluorescence deactivation processes. Furthermore, leuco forms present much higher Stokes shifts compared with keto ones, suggesting an excited-state geometry different from the ground-state geometry, possibly involving rotational photoisomerization.

IT 75038-06-1, Leuco indirubin
RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(photophys. and spectroscopic studies of indigo derivs. in their keto and leuco forms)
RN 75038-06-1 CAPLUS
CN [2,3'-Bi-1H-indole]-2',3-diol (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:493561 CAPLUS
DOCUMENT NUMBER: 141:54365
TITLE: Preparation of 1,3,5-triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis
INVENTOR(S): Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 300 pp., Cont. of U.S. Ser. No. 85,053, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004116388	A1	20040617	US 2003-699518		20031031
US 7074789	B2	20060711			
PRIORITY APPLN. INFO.:			US 1999-158176P	P	19991007
			US 1999-166978P	P	19991123
			US 1999-170378P	P	19991213
			US 2000-183263P	P	20000217
			US 2000-215576P	P	20000630
			US 2000-219801P	P	20000720
			US 2000-685053	B1	20001006

OTHER SOURCE(S): MARPAT 141:54365
GI



AB Title compds. I [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, (un)substituted heterocyclyl, alkyl; R3 = independently aryl, (un)substituted Ph, heteroaryl; R5 = independently H, alkynyl, cycloalkenyl, aryl, R9, (un)substituted (cyclo)alkyl, alkenyl; R6 = independently COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, SO1-2R5; R8 = independently (un)substituted (hetero)monocyclyl, (hetero)bicyclyl, (hetero)tricyclyl] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. Examples include a number of general synthetic methods, specific exptl. details for the preparation of selected invention compds., and phys. and bioassay data. For instance, 2,4-dichloro-1,3,5-triazine was coupled with 3,4,5-trimethoxyaniline in the presence of diisopropylethylamine in DMF to give the triazinamine (37%). Subsequent reaction with 4-aminoveratrole using diisopropylethylamine in EtOH provided II (66%). The latter was one of over 950 invention compds. tested for activity against the EGFR-1,

L8 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IGFR-1, Akt3-1, Met-1, KDR-1, Zap-1, Lck-1, Itk-1, PDGFRB-1, Tek-1, ErbB2-2, EPHB4-1, ErbB4-1, FGFR1-1, Flt-1, Fyn-1, Hck-1, Lyn-1, Ret-1, and/or Src-1 receptors with IC50 values in ranges from <0.4 μg/mL to >4.5 μg/mL. Thus, I and their compns. are useful for the treatment of diseases or conditions involving angiogenesis or vasculogenesis (no data).

IT 333728-93-1P 333730-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; preparation of triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis)
RN 333728-93-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796689 CAPLUS
DOCUMENT NUMBER: 139:323431
TITLE: Preparation of heterocyclyl-substituted 2-oxindoles and 2,3-dihydro-1H-indol-2-ols as glycogen synthase kinase-3 inhibitors
INVENTOR(S): Berg, Stefan; Hellberg, Sven; Nyloef, Martin; Xue, Yafeng
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003082853	A1	20031009	WO 2003-SE508		20030328
WO 2003082853	A8	20040506			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2476343	A1	20031009	CA 2003-2476343		20030328
AU 2003216026	A1	20031013	AU 2003-216026		20030328
EP 1492785	A1	20050105	EP 2003-745498		20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008196	A	20050111	BR 2003-8196		20030328
US 2005153987	A1	20050714	US 2003-509268		20030328
CN 1642938	A	20050720	CN 2003-807389		20030328
JP 2005526814	T	20050908	JP 2003-580319		20030328
CN 1923812	A	20070307	CN 2006-10153714		20030328
ZA 2004007665	A	20050829	ZA 2004-7665		20040922
NO 2004004432	A	20041019	NO 2004-4432		20041019
PRIORITY APPLN. INFO.:			SE 2002-979	A	20020328
			CN 2003-807389	A3	20030328
			WO 2003-SE508	W	20030328

OTHER SOURCE(S): MARPAT 139:323431
GI



I II



III

AB Title compds. I and II [wherein P = 5- or 6-membered heteroarom. ring; R1 = H; R2 and R3 = independently halo, NO2, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, CHO, COR4, CO2R4, CH2F, CHF2, CF3, OCH2F, OCHF2, OCF3, OCO2R4, NR4OR5, NR4CO2R5, SO3R4, XR6; R4 = H, alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, alkyl-NR14R15, or (un)substituted heterocyclyl; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, or alkyl-NR14R15; or NR4R5 = (un)substituted heterocyclyl; R6 = (un)substituted Ph or heterocyclyl; R7, R9, and R12 = independently H or alkyl; R8 ,R10, R11, and R13 = independently alkyl; R14 and R15 = independently H or alkyl(cycloalkyl); or NR14R15 = (un)substituted heterocyclyl; X = direct bond, O, COR7R8, SO2NR9R10, or NR12R13; OCOR4 (un)substituted alkyl or alkoxy; m = 0-4; n = 0-4; and their pharmaceutically acceptable salts thereof] were prepared as glycogen synthase kinase-3 (GSK3) inhibitors. For example, reduction of 5-cyanooxindole with NaH in DMF, followed by coupling with 2-chloro-N-[2-(dimethylamino)ethyl]isonicotinamide in DMF provided the title indolol III (5%). In ATP competition assays, compds. of the invention inhibited recombinant human GSK3β with Ki values in the range of about 0.001 nM to about 10,000 nM (no specific values given). Thus, I, II, and their pharmaceutical formulations are useful for the treatment of a variety of neurodegenerative and dementia related diseases, including Alzheimer's disease (no data).

IT 612487-72-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-75-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-77-1P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide 612487-80-6P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 612487-82-8P, 2-Hydroxy-3-[5-[(pyrrolidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-85-1P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-87-3P, 2-Hydroxy-3-[5-[[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-07-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile 612488-09-2P, 5-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol 612488-11-6P, 5,6-Dibromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol

612488-22-9P, 3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-31-0P, 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 612488-33-2P, 3-[5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-35-4P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 612488-38-7P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 612488-41-2P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide 612488-52-5P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(GSK3 inhibitor; prepn. of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-75-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-77-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 612487-80-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-

pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 612487-82-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-85-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-87-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612488-07-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612488-09-2 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612488-11-6 CAPLUS
CN 1H-Indol-2-ol, 5,6-dibromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612488-22-9 CAPLUS
CN Piperazine, 1-[[5-bromo-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 612488-31-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 612488-33-2 CAPLUS
CN Piperazine, 1-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 612488-35-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 612488-38-7 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 612488-41-2 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 612488-52-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro- (9CI) (CA INDEX NAME)



IT 612487-68-0P, 2-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]isonicotinamide 612487-69-1P, 2-Hydroxy-3-[4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-70-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-71-5P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-73-7P, 2-Hydroxy-3-[6-[2-(morpholin-4-yl)ethoxy]pyrimidin-4-yl]-1H-indole-5-carbonitrile 612487-74-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-76-0P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride 612487-78-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-79-3P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 612487-81-7P, 2-Hydroxy-3-[5-[(pyrrolidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-83-9P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-86-2P, 2-Hydroxy-3-[5-[[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-88-4P, 3-[5-[[3-(Dimethylamino)pyrrolidin-1-yl]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-89-5P, 2-Hydroxy-3-[5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-90-8P, 2-Hydroxy-3-[5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-91-9P, 3-[5-[(Azetidin-1-yl)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-92-0P, 2-Hydroxy-3-[5-[[4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-93-1P, 3-[5-[[(2-Cyanoethyl)(ethyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-94-2P, 3-[5-[[(4-Chlorobenzyl)(methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-95-3P, 3-[5-[[[(2-Furyl)methyl](methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-96-4P, 2-Hydroxy-3-[5-

[[methyl(phenyl)amino]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-97-5P, 2-Hydroxy-3-[5-[(3-methylpiperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-98-6P, 3-[5-[[Cyclohexyl(methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-99-7P, 2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-00-3P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-01-4P, 6-Chloro-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-03-6P, 3-[5-[(Morpholin-4-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-05-8P, 6-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-06-9P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-08-1P, 5-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-10-5P, 5,6-Dibromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-14-9P, 3-[5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-15-0P, 2-Hydroxy-3-[5-[[4-(3-methylbutyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-16-1P, 2-Hydroxy-3-[5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-17-2P, 3-[5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-18-3P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(pyridin-3-yl)-1H-indol-2-ol 612488-19-4P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(thien-2-yl)-1H-indol-2-ol hydrochloride 612488-20-7P, 5-(2-Furyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-21-8P, 3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-23-0P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol hydrochloride 612488-24-1P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-25-2P, N-[(1-Ethylpyrrolidin-2-yl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride 612488-26-3P, 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(morpholin-4-yl)ethyl]nicotinamide hydrochloride 612488-27-4P, 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)nicotinamide hydrochloride 612488-28-5P, 5-Nitro-3-[5-[(4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl]pyridin-2-yl)-1H-indol-2-ol hydrochloride 612488-29-6P, 3-[5-[(3-(Dimethylamino)pyrrolidin-1-yl]carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-30-9P, N-[2-(Dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride 612488-32-1P, 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide fumarate 612488-34-3P, 3-[5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol fumarate 612488-36-5P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide fumarate 612488-37-6P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 612488-40-1P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide fumarate 612488-42-3P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide fumarate 612488-43-4P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide 612488-44-5P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-45-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-46-7P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(2-methylthiazol-4-

yl)-1H-indol-2-ol hydrochloride 612488-48-9P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(thiazol-4-yl)-1H-indol-2-ol fumarate 612488-49-0P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(oxazol-5-yl)-1H-indol-2-ol 612488-50-3P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-55-8P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide fumarate 612488-57-0P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile fumarate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GSK3 inhibitor; prepn. of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-68-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 612487-69-1 CAPLUS
CN Piperazine, 1-[[2-(5-cyano-2-hydroxy-1H-indol-3-yl)-4-pyridinyl]carbonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-70-4 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 612487-71-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-

pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-73-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 612487-74-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-76-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-83-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-86-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-88-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



●x HCl

RN 612487-78-2 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-79-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612487-81-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 612487-89-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperidinyl)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-90-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-phenyl-1-piperazinyl)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-91-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-(1-azetidinylmethyl)-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-92-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-93-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[(2-cyanoethyl)ethylamino]methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-94-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-95-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[(2-furanylmethyl)methylamino]methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-96-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(methylphenylamino)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-97-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(3-methyl-1-piperidinyl)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-98-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(cyclohexylmethylamino)methyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 612487-99-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612488-00-3 CAPLUS
CN Piperazine, 1-[[6-(2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-01-4 CAPLUS
CN Piperazine, 1-[[6-(6-chloro-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-03-6 CAPLUS
CN Morpholine, 4-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 612488-05-8 CAPLUS
CN 1H-Indol-2-ol, 6-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-06-9 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-08-1 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-10-5 CAPLUS
CN 1H-Indol-2-ol, 5,6-dibromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-14-9 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-15-0 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-(3-methylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-16-1 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-17-2 CAPLUS
CN Piperazine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-ethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-18-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 612488-19-4 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(2-thienyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-20-7 CAPLUS
CN 1H-Indol-2-ol, 5-(2-furanyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-21-8 CAPLUS
CN Piperazine, 1-[[5-bromo-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-23-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-24-1 CAPLUS
CN Piperazine, 1-[[6-(6-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(4-morpholinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methyl-4-piperidinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-28-5 CAPLUS
CN Piperidine, 1-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-(1-pyrrolidinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-29-6 CAPLUS
CN 3-Pyrrolidinamine, 1-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-30-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-32-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-31-0
CMF C20 H21 N5 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-34-3 CAPLUS
CN Piperazine, 1-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-33-2
CMF C19 H19 N5 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-35-4
CMF C21 H21 N5 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-37-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-40-1 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-39-8
CMF C18 H19 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-42-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-41-2
CMF C20 H23 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-43-4 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 612488-44-5 CAPLUS
CN 1H-1,4-Diazepine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 612488-45-6 CAPLUS
CN Morpholine, 4-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 612488-46-7 CAPLUS
CN Piperazine, 1-[[6-[2-hydroxy-5-(2-methyl-4-thiazolyl)-1H-indol-3-yl]-3-pyridinyl]sulfonyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-48-9 CAPLUS
CN Piperazine, 1-[[6-[2-hydroxy-5-(4-thiazolyl)-1H-indol-3-yl]-3-pyridinyl]sulfonyl]-4-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-47-8
CMF C21 H21 N5 O3 S2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-49-0 CAPLUS
CN Piperazine, 1-[[6-[2-hydroxy-5-(5-oxazolyl)-1H-indol-3-yl]-3-pyridinyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 612488-50-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 612488-55-8 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-43-4
CMF C21 H23 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-57-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]hexahydro-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-44-5
CMF C20 H21 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 612487-59-9P 612487-60-2P 612487-65-7P, 3-[5-[(Morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-5-(pyridin-3-yl)-1H-indol-2-ol 612487-66-8P, 3-[5-[(Morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-5-(thien-2-yl)-1H-indol-2-ol 612487-67-9P, 5-(2-Furyl)-3-[5-[(morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-1H-indol-2-ol 612487-84-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-59-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 612487-60-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 612487-65-7 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 612487-66-8 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 612487-67-9 CAPLUS
CN 1H-Indol-2-ol, 5-(2-furanyl)-3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 612487-84-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-oxido-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:532662 CAPLUS
DOCUMENT NUMBER: 139:101026
TITLE: Preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compositions for treatment of neurodegenerative diseases
INVENTOR(S): Berg, Stefan; Bhat, Ratan; Edwards, Philip; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055877	A1	20030710	WO 2002-SE2371	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002359162	A1	20030715	AU 2002-359162	20021218
EP 1458711	A1	20040922	EP 2002-793676	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516961	T	20050609	JP 2003-556407	20021218
US 2005222181	A1	20051006	US 2004-499388	20040617
PRIORITY APPLN. INFO.:			US 2001-344885P P	20011221
			WO 2002-SE2371 W	20021218

OTHER SOURCE(S): MARPAT 139:101026
GI



AB 2-Oxindoles, such as I [R = substituted- or unsubstituted-quinazolin-4-yl; R2 = OH, CH2F, CF3, OCF3, CN, NH2, NO2, alkyl, alkoxy, acyloxy, acyl, alkylthio, etc.; m = 0-4], were prepared for therapeutic use as GSK3 inhibitors. These oxindoles are intended for therapeutic use in the treatment of GSK3 associated diseases, such as Alzheimer's disease, dementia,

Parkinson dementia complex of Guam, frontotemporal dementia Parkinson's type, HIV dementia, neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, dementia pugilistic and age related cognitive disorders, as well as for male contraception and treatment of diabetes, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's disease, Parkinson's disease, postencephelatic Parkinsonism, progressive supranuclear palsy, Pick's disease, Niemann-Pick's disease, stroke, head trauma, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorders and androgenetic alopecia. Thus, oxindole II was prepd. in 99% yield by a coupling reaction of Me 2-oxo-5-indolinecarboxylate with 4-chloro-7-(2-methoxyethoxy)quinazoline in DMF using NaH. The prepd. oxindoles were tested for GSK3 inhibition using the GSK3β proximity assay.

IT 556824-44-3P 556824-45-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of neurodegenerative diseases)

RN 556824-44-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 556824-45-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



IT 556824-47-6P 556824-48-7P 556824-49-8P
556824-50-1P 556824-51-2P 556824-52-3P
556824-53-4P 556824-54-5P 556824-55-6P
556824-56-7P 556824-57-8P 556824-58-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of

neurodegenerative diseases)

RN 556824-47-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[3-(methylphenylamino)propyl]- (9CI) (CA INDEX NAME)



RN 556824-48-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[3-(1-hydroxyethyl)phenyl]-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 556824-49-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 556824-50-1 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-cyclohexylphenyl)-2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 556824-51-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[2-(5-methyl-1H-indol-3-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 556824-52-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 556824-53-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4,4-diethoxybutyl)-2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 556824-54-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[1-(phenylmethyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 556824-55-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[3-(1-hydroxyethyl)phenyl]-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 556824-56-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-(4-cyclohexylphenyl)-2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 556824-57-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[2-(5-methyl-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 556824-58-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532526 CAPLUS
DOCUMENT NUMBER: 139:101024
TITLE: Preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compositions for treatment of neurodegenerative diseases
INVENTOR(S): Berg, Stefan; Bhat, Ratan; Edwards, Philip; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055492	A1	20030710	WO 2002-SE2370	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002359161	A1	20030715	AU 2002-359161	20021218
EP 1458394	A1	20040922	EP 2002-793675	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516960	T	20050609	JP 2003-556069	20021218
US 2005070559	A1	20050331	US 2004-499950	20041112
PRIORITY APPLN. INFO.:			US 2001-344887P P	20011221
			WO 2002-SE2370 W	20021218

OTHER SOURCE(S): MARPAT 139:101024
GI


I


II

AB 2-Oxindoles, such as I [R = substituted- or unsubstituted-quinazolin-4-yl; R2 = OH, CH2F, CF3, OCF3, CN, NH2, NO2, alkyl, alkoxy, acyloxy, acyl, alkylthio, etc.; m = 0-4], were prepared for therapeutic use as GSK3 inhibitors. These oxindoles are intended for therapeutic use in the treatment of GSK3 associated diseases, such as Alzheimer's disease, dementia,

L8 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(prepn. of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of neurodegenerative diseases)

RN 557092-91-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 557092-92-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 557092-93-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 557092-94-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-[3-(4-morpholinyl)propyl]-'(9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Parkinson dementia complex of Guam, frontotemporal dementia Parkinson's type, HIV dementia, neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, dementia pugilistic and age related cognitive disorders, as well as for male contraception and treatment of diabetes, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's disease, Parkinson's disease, postencephelatic Parkinsonism, progressive supranuclear palsy, Pick's disease, Niemann-Pick's disease, stroke, head trauma, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorders and androgenetic alopecia. Thus, the dihydrochloride salt of oxindole II was prepd. in 68% yield by a coupling reaction of 5-cyanooxindole with 4-chloro-7-(2-morpholinoethoxy)quinazoline in DMF using NaH. The prepd. oxindoles were tested for GSK3 inhibition using the GSK3β proximity assay.

IT 556824-44-3P 556824-45-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of neurodegenerative diseases)

RN 556824-44-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 556824-45-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



IT 557092-91-8P 557092-92-9P 557092-93-0P
557092-94-1P 557092-95-2P 557092-96-3P
557092-99-6P 557093-32-0P 557093-33-1P
557093-42-2P 557093-45-5P 557093-48-8P
557093-49-9P 557093-58-0P 557093-60-4P
557093-64-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L8 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 557092-95-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[7-(2-methoxyethoxy)-4-quinazolinyl]-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 557092-96-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[7-(2-methoxyethoxy)-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 557092-99-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[7-[2-(2-methoxyethoxy)ethoxy]-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 557093-32-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[8-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 557093-33-1 CAPLUS
CN 1H-Indol-2-ol, 3-[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-6-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 557093-42-2 CAPLUS
CN 1H-Indol-2-ol, 6-ethyl-3-[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 557093-45-5 CAPLUS
CN 1H-Indol-2-ol, 6-methyl-3-[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-(9CI) (CA INDEX NAME)



RN 557093-48-8 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-6-methyl-3-[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 557093-49-9 CAPLUS
CN 1H-Indol-2-ol, 6-bromo-3-[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-5-nitro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 557093-58-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[7-[3-(dimethylamino)propoxy]-4-quinazolinyl]-2-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 557093-60-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[7-[2-(dimethylamino)ethoxy]-4-quinazolinyl]-2-hydroxy-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 557093-59-1
CMF C21 H19 N5 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 557093-64-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[7-[2-[bis(1-methylethyl)amino]ethoxy]-4-quinazolinyl]-2-hydroxy-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 557093-63-7
CMF C25 H27 N5 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:511075 CAPLUS
DOCUMENT NUMBER: 139:85242
TITLE: Preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compositions for treatment of neurodegenerative diseases
INVENTOR(S): Berg, Stefan; Bhat, Ratan; Empfield, James; Hellberg, Sven; Klimas, Michael; Woods, James
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053330	A2	20030703	WO 2002-SE2373	20021218
WO 2003053330	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002359164	A1	20030709	AU 2002-359164	20021218
EP 1458707	A2	20040922	EP 2002-793678	20021218
EP 1458707	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005513082	T	20050512	JP 2003-554090	20021218
AT 361287	T	20070515	AT 2002-793678	20021218
US 2005065170	A1	20050324	US 2004-499217	20041122
US 7205314	B2	20070417		

PRIORITY APPLN. INFO.: SE 2001-4340 A 20011220
WO 2002-SE2373 W 20021218
OTHER SOURCE(S): MARPAT 139:85242
GI


I


II

AB 2-Oxindoles, such as I [R = substituted or unsubstituted nitrogen containing

L8 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
heteroaryl, such as 2-isoquinyl, thieno[2,3-b]pyrimidin-4-yl or 5,6,7,8-tetrahydroquinazolin-4-yl; R2 = OH, CH2F, CF3, OCF3, CN, NH2, NO2, alkyl, alkoxy, acyloxy, acyl, alkylthio, etc.; m = 0-4], were prepd. for therapeutic use as GSK3 inhibitors. These oxindoles are intended for therapeutic use in the treatment of GSK3 assocd. diseases, such as Alzheimer's disease, dementia, Parkinson dementia complex of Guam, frontotemporal dementia Parkinson's type, HIV dementia, neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, dementia pugilistic and age related cognitive disorders, as well as for male contraception and treatment of diabetes, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's disease, Parkinson's disease, postencephelatic Parkinsonism, progressive supranuclear palsy, Pick's disease, Niemann-Pick's disease, stroke, head trauma, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorders and androgenetic alopecia. Thus, oxindole II was prepd. in 51% yield by a coupling reaction of 5-cyanooxindole with 1-chloro-6-(2-methoxyethoxy)isoquinoline using LDA and TMEDA in anhyd. THF under a N2 atm. The prepd. oxindoles were tested for GSK3 inhibition using the GSK3β proximity assay.
IT 556044-32-7P 556044-34-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of neurodegenerative diseases)
RN 556044-32-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-thieno[2,3-d]pyrimidin-4-yl-, methyl ester (9CI) (CA INDEX NAME)



RN 556044-34-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-(5,6,7,8-tetrahydro-4-quinazolinyl)-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:814114 CAPLUS
DOCUMENT NUMBER: 137:325434
TITLE: Preparation of triazinyl amides as angiogenesis inhibitors
INVENTOR(S): Geuns-Meyer, Stephanie D.; Dipietro, Lucian V.; Kim, Joseph L.; Patel, Vinod F.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083654	A1	20021024	WO 2002-US11675	20020411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087908	A1	20030508	US 2002-120939	20020410
US 6864255	B2	20050308		
CA 2443366	A1	20021024	CA 2002-2443366	20020411
AU 2002338645	A1	20021028	AU 2002-338645	20020411
EP 1385833	A1	20040204	EP 2002-762087	20020411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-282977P P 20010411
US 2002-120939 A 20020410
WO 2002-US11675 W 20020411
OTHER SOURCE(S): MARPAT 137:325434
GI


I


II

AB The triazinyl amides I [wherein R1 = (un)substituted Ph or heteroaryl; R2 = H, halo, R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, heterocyclyl, or (un)substituted alkyl, etc.; R3 = Ph or (un)substituted heteroaryl; R5 = H, alkynyl, acyl, R9, or (un)substituted (cyclo)alkyl or (cyclo)alkenyl, etc.; R6 = COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, or SOnR5; R8 and R9 = independently mono-, bi-, or

L8 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
tri-cyclic ring, etc.; n = 1 or 2; aryl = (un)substituted mono-, bi-, or tri-cyclic arom. ring, etc.; or analogs, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. for prophylaxis and treatment of cancer and angiogenesis-related diseases. For example, the triazinyl benzamide II was prepd. in a multiple-step synthesis including the final coupling reaction of [4-(2-chlorobenzimidazol-1-yl)-[1,3,5]triazin-2-yl]-(3,4,5-trimethoxyphenyl)amine with 3-amino-N-(4-phenoxyphenyl)benzamide in isopropanol in the presence of DIEA. I showed inhibition of KDR kinase at doses less than 50 μM.
IT 333728-93-1P 333730-27-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazinyl amides as angiogenesis inhibitors)
RN 333728-93-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:391720 CAPLUS
DOCUMENT NUMBER: 136:386144
TITLE: Preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivatives for use in treating p38 kinase-associated conditions
INVENTOR(S): Leftheris, Katerina; Barrish, Joel; Hynes, John; Wrobleski, Stephen T.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040486	A2	20020523	WO 2001-US49982	20011107
WO 2002040486	A3	20030912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2429628	A1	20020523	CA 2001-2429628	20011107
AU 200232760	A	20020527	AU 2002-32760	20011107
EE 200300227	A	20031015	EE 2003-227	20011107
EP 1363910	A2	20031126	EP 2001-992298	20011107
EP 1363910	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200303897	A2	20040301	HU 2003-3897	20011107
JP 2004522713	T	20040729	JP 2002-543494	20011107
CN 1622946	A	20050601	CN 2001-818997	20011107
NZ 525334	A	20050729	NZ 2001-525334	20011107
BR 2001015446	A	20050809	BR 2001-15446	20011107
AT 318820	T	20060315	AT 2001-992298	20011107
PT 1363910	T	20060531	PT 2001-992298	20011107
ES 2259051	T3	20060916	ES 2001-1992298	20011107
BG 107750	A	20040130	BG 2003-107750	20030421
IN 2003MN00471	A	20050304	IN 2003-MN471	20030502
MX 2003PA04290	A	20040212	MX 2003-PA4290	20030515
ZA 2003003786	A	20040816	ZA 2003-3786	20030515
NO 2003002229	A	20030716	NO 2003-2229	20030516
HK 1057555	A1	20060915	HK 2004-100424	20040119

PRIORITY APPLN. INFO.:			
	US 2000-249877P	P	20001117
	US 2001-310561P	P	20010807
	WO 2001-US49982	W	20011107

OTHER SOURCE(S): MARPAT 136:386144
GI

L8 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II



III

AB Title compds. I [R3 = H, Me, perfluoromethyl, MeO, halo, cyano, NH2; X = O, OC(O), S, S(O), SO2, C(O), CO2, amino, aminoacyl, etc. or X is absent; Z = O, S, N, and CR20, wherein when Z = CR20 said carbon atom may form an (un)(un)substituted bicyclic aryl or heteroaryl with R4 and R5; R1 = H, CH3, OH, OCH3, SH, SCH3, acyloxy, etc.; R2 = H, alkyl, alkenyl, aryl, heteroaryl, etc.; R4 = (un)substituted aryl, heteroaryl, bicyclic 7-11 membered (un)saturated carbocyclic or heterocyclic ring; R5 = H, alkyl, etc. or alternatively, R4 and R5 taken together with Z form an (un)substituted bicyclic 7-11 membered aryl or heteroaryl; R6 = H, alkyl, aryl, heterocyclo, etc.; R20 = H, alkyl, etc. with some provisions] were prepared Over 150 compds. were disclosed. For instance, 1-Amino-3-methylpyrrole-2,4-dicarboxylic acid di-Me ester was prepared from the parent pyrrole (preparation given) and diphenylphosphorylhydroxylamine and reacted with formamide (165°C, 6 h) to give intermediate pyrrolo[2,1-f][1,2,4]triazine II in 90% yield. II was converted to the imino-chloride (POCl3) and treated with indoline to give example compound III. I are inhibitors of p38 kinase and are useful for the treatment of inflammatory disorders.

IT 310443-55-1P, 4-[6-Fluoro-2-hydroxy-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester
310443-56-2P, 4-[6-Bromo-2-hydroxy-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs.
for use in treating p38 kinase-associated conditions)

RN 310443-55-1 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(6-fluoro-2-hydroxy-1H-indol-3-yl)-5-methyl-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 310443-56-2 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(6-bromo-2-hydroxy-1H-indol-3-yl)-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:265404 CAPLUS
DOCUMENT NUMBER: 134:295842
TITLE: Preparation of triazine kinase inhibitors
INVENTOR(S): Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Geuns-Meyer, Stephanie D.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian
PATENT ASSIGNEE(S): Kinetix Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025220	A1	20010412	WO 2000-US27811	20001006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386218	A1	20010412	CA 2000-2386218	20001006
EP 1218360	A1	20020703	EP 2000-972036	20001006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511378	T	20030325	JP 2001-528166	20001006
AU 770600	B2	20040226	AU 2001-10754	20001006
MX 2002PA03436	A	20020820	MX 2002-PA3436	20020404

PRIORITY APPLN. INFO.:			
	US 1999-158176P	P	19991007
	US 1999-166978P	P	19991123
	US 1999-170378P	P	19991213
	US 2000-183263P	P	20000217
	US 2000-215576P	P	20000630
	US 2000-219801P	P	20000720
	WO 2000-US27811	W	20001006

OTHER SOURCE(S): MARPAT 134:295842
GI



I II

AB Title triazine compds. (I) [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, or (un)substituted heterocyclyl or alkyl; R3 = independently aryl or (un)substituted Ph or heteroaryl; R5 = independently H, (un)substituted

L8 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(cyclo)alkyl or alkenyl, alkynyl, cycloalkenyl, aryl, or haloalkyl; R6 = independently COR5, CO2R5, CONR5R5, C(NR5)NR5R5, or SOnR5; R8 = independently (un)substituted mono-, di-, or tricyclic ring system comprising 1-3, 1-6, or 1-9 heteroatoms, resp.; n = 1-2] were prepd. as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. For example, amination of 2,4-dichloro-1,3,5-triazine (prepn. given) with 3,4,5-trimethoxyaniline in DMF, followed by a second amination with 4-aminoveratrole in the presence of diisopropylethylamine in EtOH, yielded II. In kinase inhibition studies, II gave IC50 values of < 0.4 μg/mL for KDR-1, PDGFRB-1, and Flt-1; 0.4 to 2.4 μg/mL for Lck-1; 3.5 to 4.5 μg/mL for EGFR-1, Tek-1, and EPGB4-1; and > 4.5 μg/mL for IGFR-1, AKT3-1, Met-1, Zap-1, Itk-1, FGFR1-1, and Fyn-1. I and compns. comprising them are useful for the treatment of disease or disease symptoms related to kinase inhibition, such as angiogenesis or vasculogenesis (no data).

IT 333728-93-1P 333730-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazine kinase inhibitors for inhibiting angiogenesis or vasculogenesis)

RN 333728-93-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:841986 CAPLUS
DOCUMENT NUMBER: 134:17506
TITLE: Preparation of pyrrolotriazines as kinases inhibitors for treating inflammation, cancer, and proliferative diseases
INVENTOR(S): Hunt, John T.; Bhide, Rajeev S.; Borzilleri, Robert M.; Qian, Ligang
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071129	A1	20001130	WO 2000-US13420	20000516
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373990	A1	20001130	CA 2000-2373990	20000516
CA 2373990	C	20070508		
EP 1183033	A1	20020306	EP 2000-930761	20000516
EP 1183033	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 2000010482	A	20020423	BR 2000-10482	20000516
JP 2003500359	T	20030107	JP 2000-619433	20000516
HU 200301005	A2	20030728	HU 2003-1005	20000516
HU 200301005	A3	20060529		
NZ 516292	A	20040130	NZ 2000-516292	20000516
AU 770377	B2	20040219	AU 2000-48524	20000516
TR 200103352	T2	20050321	TR 2001-3352	20000516
AT 318603	T	20060315	AT 2000-930761	20000516
EP 1669071	A1	20060614	EP 2006-3602	20000516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES 2258459	T3	20060901	ES 2000-930761	20000516
TW 238163	B	20050821	TW 2000-89109521	20000518
US 6982265	B1	20060103	US 2000-573829	20000518
IN 2001MN01414	A	20050304	IN 2001-MN1414	20011113
MX 2001PA11832	A	20020621	MX 2001-PA11832	20011119
NO 2001005650	A	20011120	NO 2001-5650	20011120
NO 322214	B1	20060828		
ZA 2001009577	A	20030220	ZA 2001-9577	20011120
HK 1041599	A1	20060915	HK 2002-103297	20020502
US 2006004007	A1	20060105	US 2005-190412	20050727
US 7112675	B2	20060926		
US 2006128709	A1	20060615	US 2006-345845	20060202

PRIORITY APPLN. INFO.:

US 1999-135265P	P	19990521
US 2000-193727P	P	20000331
EP 2000-930761	A3	20000516
WO 2000-US13420	W	20000516
US 2000-573829	A3	20000518

L8 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
US 2005-190412 A3 20050727

OTHER SOURCE(S): MARPAT 134:17506

GI



I



II

AB Title compds. [I; X, Y independently = O, OCO, S, SO, SO2, CO, CO2, NH, NHCO, NHCONH, bond; Z = O, S, N, CH; R1 = H, CH3, OH, OCH3, SH, SCH3, NH2, CO2H, NO2, CN, halo; R2, R3 independently = H, alkyl, alkenyl, alkynyl, aryl, heterocyclo; R4, R5 independently = H, alkyl, aryl, heterocyclo; R4-R5 = monocyclic 5-7 membered cyclic ring, bicyclic 7-11 membered cyclic ring; R6 = H, alkyl, aryl, heterocyclo, halo], enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, carriers, and solvates, which inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2 and produce antiangiogenic effect, are prepared Title compds. I are useful as anti-cancer agents, antiinflammatories and agents for the treatment of diseases associated with signal transduction pathways operating through growth factor receptors. Thus, the title compound II was prepared

IT 310443-55-1P 310443-56-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolotriazines as kinases inhibitors useful in treating inflammation, cancer, and proliferative diseases)

RN 310443-55-1 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(6-fluoro-2-hydroxy-1H-indol-3-yl)-5-methyl-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 310443-56-2 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(6-bromo-2-hydroxy-1H-indol-3-yl)-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:559183 CAPLUS
DOCUMENT NUMBER: 93:159183
TITLE: Photosensitive layer material for electrophotographic purposes
INVENTOR(S): Sakuma, Seiiti; Karasawa, Shuichi
PATENT ASSIGNEE(S): Ricoh Co., Ltd., Japan
SOURCE: Ger. Offen., 56 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2938129	A1	19800327	DE 1979-2938129	19790920
DE 2938129	C2	19830714		
JP 55043579	A	19800327	JP 1978-117273	19780922
JP 55089849	A	19800707	JP 1978-163059	19781228
JP 55089850	A	19800707	JP 1978-163060	19781228
JP 55089852	A	19800707	JP 1978-163062	19781228

PRIORITY APPLN. INFO.:
JP 1978-117273 A 19780922
JP 1978-163059 A 19781228
JP 1978-163060 A 19781228
JP 1978-163062 A 19781228

AB A photosensitive element for electrophotog. comprises a conducting support with a 1st photoconducting layer having sensitivity to a portion of the visible region (light A) and a 2nd photoconducting layer which is transparent to light A but sensitive to another region(light B). The two layers hold charges of opposite polarity and maintain a surface potential sufficient for development of an electrostatic latent image with a toner. Pos.-neg. charging is attained by use of some combination of colored pigments, dyes, electron donors plus acceptors, colorless pigments plus dyes with photoconductors of p-type, electron donors, photoconductors of n-type, electron acceptors, or a combination of n-type and p-type photoconductors. The colored pigments include amorphous Se containing spectral sensitizers, Cu-doped CdS, etc., and azo, quinone, indigo, bisbenzimidazole, phthalocyanine, quinacridone, and perylene pigments. The colorless pigments include TiO2 and ZnO. The dyes include diphenylmethane, triphenylmethane, xanthene, acridine, azine, thiazine, and pycylium dyes. The electron acceptors include acid anhydrides and nitro and cyano compds. The electron donors include amines, anthracene derivs., and heterocyclic N compds. The materials give 2-color reproductions from multicolor originals with a single exposure. Thus, on an Al-coated polyester support an amorphous Se layer was evaporated to give a
1-μm charge-forming layer to which was applied a solution containing polycarbonate resin 5 and 1,1-bis(p-dibenzylaminophenyl)propane 5 in CH2Cl2 90 parts and the coating was dried 10 min at 80° to give a 5-μm charge-transfer layer; this comprises the 1st photoconducting layer. Then β-Cu phthalocyanine 25, poly(N-vinylcarbazole) 68, and polyester resin 7 were added to THF 90 parts and the mixture was ball-milled 5 h and then applied to the 1st photoconducting layer and air-dried 5 min and heated 10 min at 110° to give a 4-μm 2nd photoconducting layer. This photosensitive material was charged by exposure in the dark to a halogen lamp for 30 lx-s and then imagewise exposed to an original with black, red, blue, and white regions and automatically developed with a black toner. The red and blue regions were reproduced with lower d. than the black regions and the white images were free of background specks. The black and white images were distinct and showed high

L8 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
contrast.
IT 75038-06-1
RL: USES (Uses)
(electron acceptor, in electrophotog. layers)
RN 75038-06-1 CAPLUS
CN [2,3'-Bi-1H-indole]-2',3-diol (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1967:516779 CAPLUS
DOCUMENT NUMBER: 67:116779
TITLE: Enolizable cyclic ketones. I. Reaction with activated heteroaromatic N-oxides
AUTHOR(S): Bruni, Paolo; Guerra, Guido
CORPORATE SOURCE: Univ. Bologna, Bologna, Italy
SOURCE: Annali di Chimica (Rome, Italy) (1967), 57(6), 688-97
CODEN: ANCRAI; ISSN: 0003-4592
DOCUMENT TYPE: Journal
LANGUAGE: Italian
AB cf. CA 56: 7156d. Cyclohexanone reacted with anhydrous quinoline N-oxide (I)
in BzCl-CHCl3 solution at room temperature 30 days to give red-orange 2-(2-quinolyl)cyclohexanone, m. 120-1° (EtOH). Similarly, acenaphthenone and I gave 15% red 2-(2-quinolyl)acenaphthenone, m. 211-12°, and 2-indolinone (II) and I gave 2-hydroxy-3-(2-quinolyl)indole (III), m. 284-6°. Oxidation of III with H2O2-AcOH gave quinaldine N-oxide, m. 160°. II and isoquinoline N-oxide (IV) in BzCl-CHCl3 solution reacted in 10 days at room temperature to furnish 2-hydroxy-3-(1-isoquinolyl)indole, m. 225° (pyridine-ligroine). 1-Methyl-2-indolinone (V) and I kept 48 hrs. gave 1-methyl-2-hydroxy-3-(2-quinolyl)indole, m. 220-1°. Similarly, IV and V condense to orange 1-methyl-2-hydroxy-3-(1-isoquinolyl)indole, m. 153-4°. 2-Pyrimidazolone (VI) hydrochloride and I gave in 5 hrs. at room temperature yellow 2-hydroxy-3-(2-quinolyl)pyrimidazolone, m. 290-2°. Similarly, VI and IV gave in 12 hrs. 2-hydroxy-3-(1-isoquinolyl)pyrimidazolone, m. 299-301°.
IT 16176-50-4P 16176-51-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16176-50-4 CAPLUS
CN Indol-2-ol, 3-(2-quinolyl)- (8CI) (CA INDEX NAME)



RN 16176-51-5 CAPLUS
CN Indol-2-ol, 3-(1-isoquinolyl)- (8CI) (CA INDEX NAME)



L8 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1967:47300 CAPLUS
DOCUMENT NUMBER: 66:47300
TITLE: Synthesis of a vat polymer, poly(5,5'-biisatyl[thiophene]indophenine)
AUTHOR(S): Shopov, Ivan
CORPORATE SOURCE: Bulgarian Acad. Sci., Sofia, Bulg.
SOURCE: Journal of Polymer Science, Polymer Letters Edition (1966), 4(12), 1023-8
CODEN: JPYBAN; ISSN: 0360-6384
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The title polymer (I), prepared by polycondensation of thiophene (II) and 5,5'-biisatyl (III), was reduced to its leuco form (IV) to give a polymer vat dye, which oxidized in air to give a polymer with photoelec. and semiconductive properties. Thus, 1.68 g. II in 75 ml. AcOH was added to a cooled solution of 2.92 g. III in 150 ml. H2SO4. The solution changed from dark
red to dark blue-green with a slight exotherm. After stirring 1 hr., the polymer was precipitated in H2O, washed with H2O, extracted with EtOH, and dried to
yield 94% I, a dark-blue powder. An aqueous solution of 1.6 g. Na2S2O6, 2 g.
NaOH, 1 g. I, and 60 ml. H2O turned darkbrown under N. Filtration under N left IV, which dyed cotton and linen dark-blue. In air, IV oxidized and repptd. I. The oxidation rate was increased by acidifying the solution and using Na2S as a reducing agent. I had an intensive E.P.R. signal, showed a dark conductivity which decreased with increasing temperature and illumination, and
was a p-type semiconductor. I gradually carbonized, but did not burn upon heating.
IT 32198-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32198-46-2 CAPLUS
CN Poly[(2,2'-dihydroxy[5,5'-bi-1H-indole]-3,3'-diyl)[2,2'-bithiophene]-5,5'-diyl] (9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1950:26063 CAPLUS
DOCUMENT NUMBER: 44:26063
ORIGINAL REFERENCE NO.: 44:5100h-i,5101a-i,5102a-f
TITLE: Indoxyl red
AUTHOR(S): Seidel, Paul
CORPORATE SOURCE: Daisbach, Baden, Germany
SOURCE: Chemische Berichte (1950), 83, 20-6
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.

AB The reactions of Indoxyl red (α-β'-indolyl-β-indolone) (I) with oxindole (II), NaHSO3, alkali, KMnO4, and with NaNO2 are re-investigated. On keeping I, purified via its NaHSO3 compound, in C5H5N and removing the dimer of I [cf. C.A. 44, 605d], a blue-black dye of the composition C32H2002N4 (III), needles with a blue-gray sheen, is isolated from the dark red mother liquor in 15% yield. III gives a yellow vat with alkaline Na2S2O4 and dissolves in concentrated H2SO4 with dark green color. When a specially purified I from which the last traces of NaHSO3 have been removed by crystallization from C6H6 is used, up to 30% III is obtained. III is purified via its vat to remove a small amount of dehydro-α'-desoxyindirubin. III has the structure of a diindoxylindigo. It gives a pale bluish green color with alc. KOH, a blue solution in AcOH or C5H5N, a deep blue color in cold AcOH and HCl, and a deep violet solution in hot AcOH and HCl. Treating 5 g. I with 2.7 g. II in 60 cc. AcOH gives 6.7 g. α-oxindolyl-α-indolylisatin (IV), large light yellow crystals, m. 208° after sintering. IV dissolves in alc. KOH with bluish green color. When 1 g. I is treated in the cold with 20 cc. 10% KOH saturated with SO2, a slightly soluble NaHSO3 addition compound is formed, from which I is quantitatively recovered on addition of alkali. When, however, the mixture is heated 15 min., a deep blue solution is formed and I can no longer be recovered. On acidification a mixture of 2 compds. is precipitated which are separated with very dilute Na2CO3 in which the blue-black sulfonic acid, C16H1004N2S.H2O (V), is soluble, whereas a red-brown dye, α-β'-oxindolyl-β-indolone (VI), is insol. V gradually splits off the SO3H group with the formation of VI. When the solution of V in Na2CO3 is warmed with alkali and the blue solution is acidified, a yellow sulfonic acid (VII), large yellow needles, decomposing at about 300°, is precipitated Its solution in concentrated H2SO4 is yellow and on slow dilution VII seps. as large yellow plates. With alkali at 150° VII is cleaved into II and o-H2NC6H4CO2H (VIII). When 10 g. I is intimately mixed with 100 cc. KOH (50° B.acte.e.) at 70°, the mixture slowly heated at 145°, cooled, and diluted with 300 cc. H2O, 4 g. β-diindylisatin (IX), colorless crystals from Me2CO, m. 310°, is filtered off. Acidification of the filtrate gives 3.5 g. indolealdehyde-(3) (2-carboxyanil) (X), m. 268°, which boiled 2 hrs. with 2% Na2CO3 gives VIII and β-indolealdehyde, pale yellow leaflets, m. 195°. IX is also obtained in good yield when isatin is treated in AcOH with 2 mols. indole. I (6 g.) in 100 cc. AcOH is poured into an excess of cold dilute NaOH, the very finely divided I filtered, washed, and suspended in 100 cc. H2O, 2 cc. NaOH (40° B.acte.e.) is added, the mixture cooled at 0°, and 2.5 g. KMnO4 in 100 cc. H2O is added.

L8 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

After 12 hrs. the colorless filtrate is evapd. in vacuo and acidified with AcOH, giving 0.5 g. β-indolecarboxylic acid 2-carboxyanilide (XI), crystals from AcOH, m. 248°. When 25 g. I in 1 l. AcOH is gradually treated at 10° with 6.9 g. NaNO2 over a period of 12 hrs., 15 g. Indoxyl brown (XII), C32H1804N2, red-brown leaflets, m. 410°, is obtained. Diln. of the filtrate with 1 l. H2O gives 10 g. indolyl-o-hydroxyphenylglyoxylic acid (XIII), crystals from AcOH, m. 217°. XII dissolves in concd. H2SO4 with black-brown color and is pptd. from this soln. on slow diln. After mixing 1 g. XII with 2 cc. KOH (50° B.acte.e.) and 10 cc. H2O, the K salt, large, almost black needles, seps. It is not changed when heated with KOH at 150°, but at 250° it is decompd. with the formation of α-phenylindole, m. 187° (oxime m. 258°). XII (1 g.) treated with 1.5 g. Na2S2O4 in 40 cc. H2O and 2 cc. KOH (50° B.acte.e.) gives a yellow-brown vat, from which air regenerates XII. Treatment of 1 g. XII in 10 cc. 60% EtOH with 1.5 g. Na2S2O4 gives the free leuco compd. which, shaken with Ac2O, gives the Ac deriv., (C16H1002NAc)2. Boiling 1 g. XIII 2 hrs. with 2 g. Na2CO3 in 60 cc. H2O gives indole and o-hydroxyphenylglyoxylic acid (phenylhydrazone m. 148°). On reduction of XIII with Na2S2O4 in alk. soln., 1 mol. H is taken up, giving a compd., C16H13O3N, crystals from 50% AcOH, m. 187°, of the structure XIV.

IT 848997-67-1P, Pseudoindoxyl, 2-(2-hydroxy-3-indolyl)-2-(3-indolyl)-
854233-01-5P, [2,3'-Biindol]-3(2H)-one, 2'-hydroxy-
RL: PREP (Preparation)
(preparation of)

RN 848997-67-1 CAPLUS
CN Pseudoindoxyl, 2-(2-hydroxy-3-indolyl)-2-(3-indolyl)- (5CI) (CA INDEX NAME)





RN 854233-01-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L8 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1934:44956 CAPLUS
DOCUMENT NUMBER: 28:44956
ORIGINAL REFERENCE NO.: 28:5439b-f
TITLE: The existence of favored substitution positions in biphenylene sulfide
AUTHOR(S): Courtot, Charles; Kelner, Izaak
SOURCE: Compt. rend. (1934), 198, 2003-5
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.

AB Biphenylene sulfide sulfone chloride with Zn in boiling H2O gave biphenylene sulfide-monosulfinic acid (I); monohydrate, m. 121°; Na and Ba salts, crystalline, soluble in H2O, acid oxidized in air to the hydrate of the sulfonic acid, m. 172°. I + SOCl2 gave an unstable chloride which reacted with biphenylene sulfide in presence of AlCl3 in CS2 to give (C6H4.S.C6H4]2SO, m. 260°. I + Zn in H2O at 15° gave the disulfide of biphenylene sulfide, m. 175°. Excess of Zn at 90° gave the thiol of biphenylene sulfide (II), m. 81°; Ac derivative, m. 122°; Bz derivative (III), m. 116°; Et ether (by action of EtBr), m. 93°. II was also made from nitrobiphenylene sulfide (C. A. 25, 4872) by reducing, diazotizing, treating with Et xanthate, and hydrolyzing the resulting thioxanthic ester with KOH to the K salt of II. This with BzCl gave III. Therefore the NO2 and SO3H groups enter the biphenylene sulfide mol. in the same position. Nitration of bromobiphenylene sulfide and bromination of nitrobiphenylene sulfide gave identical mononitromonobromobiphenylene sulfides (IV) which were also compared as acetates and benzoates of the corresponding bromoamino compds. Similarly the same nitrobiphenylene sulfide-sulfonic acid (chloride m. 257°) was obtained regardless of the order of substitution. Reduction of IV followed by the Sandmeyer reaction gave dibromobiphenylene sulfide, m. 229°, identical with that obtained by direct bromination. It is concluded that the 2 substituents occupy sym. positions, with respect to the S and biphenylene linkage, in both rings. Cf. C. A. 20, 2155.

IT 876480-91-0P, 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)-
RL: PREP (Preparation)
(preparation of)

RN 876480-91-0 CAPLUS
CN 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)- (3CI) (CA INDEX NAME)



L8 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1934:44955 CAPLUS
DOCUMENT NUMBER: 28:44955
ORIGINAL REFERENCE NO.: 28:5438f-i,5439a-b
TITLE: Reaction of ninhydrin and isatin with proline and hydroxyproline
AUTHOR(S): Grassmann, W.; v. Arnim, K.
SOURCE: Ann. (1934), 509, 288-303
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB Triketohydrindene hydrate (I) (2.2 mols.) and 1 mol. proline (II) in H2O at pH 7 at 60° give 83% of the dye III or IV (R = H), m. 176° (decomposition); this results in smaller yields from 2 mols. I and 1 mol. pyrrolidine (V) in boiling AcOH. I (1 mol.) and 1 mol. II in EtOH give 82% of monopyrrolidinylninhydrin, golden yellow, decomposing above 190°; with I at pH 7 68.6% of III results. I and hydroxyproline (VI) in H2O of pH 7 at 40-50° give 76% of a violet dye, III or IV (R = OH), does not m. 275°. I and piperidine (VII) in EtOH give 59% of dipiperidylninhydrin, yellow, m. 131° (decomposition); this is converted by boiling Ac2O to the dye, C23H15O4N, violet with metallic luster; this dye also results from 2 mols. I and 1 mol. VII or 1 mol. piperidine-2-carboxylic acid in AcOH; yields, about 60%. Isatin (2 mols.) and 1 mol. II in AcOH give 75.5% of a dye VIII or IX (R = H), blue needles; in H2O the yield is 46.8%; V gives the same dye; reduction with Zn or TiCl3 gives the leuco compound VI gives 57% of a dye (VIII or IX, R = OH), amorphous. Absorption spectra curves are given for these dyes. The structures of the intermediate compds. are discussed.
IT 857792-04-2P, Isopyrroline, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)- 876480-91-0P, 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)-
RL: PREP (Preparation)
(preparation of)
RN 857792-04-2 CAPLUS
CN Isopyrroline, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)- (3CI) (CA INDEX NAME)



RN 876480-91-0 CAPLUS
CN 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)- (3CI) (CA INDEX NAME)



L8 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1926:27823 CAPLUS
DOCUMENT NUMBER: 20:27823
ORIGINAL REFERENCE NO.: 20:3455h-i,3456a-d
TITLE: The methylisoindigotins and methylindirubins
AUTHOR(S): Wahl, A.; Faivret, Th.
SOURCE: Annali di Chimica Applicata (1926), 5, 314-62
CODEN: ACAPAR; ISSN: 0365-1037
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C. A. 20, 758. Methods are given for preparing 7- (I) and 5 methylisatin (II). The reduction of II with NaHSO3 gave 7-methyldioxindole m. 212°. Similarly 5-methyldioxindole, m. 210°, was prepared from I. Reduction of these 2 dioxindoles with Na-Hg gave the corresponding methyloxindoles. Isatin was reduced catalytically to isatide, which was identified by its tetra-Ac derivative, m. 221°. Similarly the reduction of II gave 5,5'-dimethylisatide, m. 230-2°. No reduction product could be obtained from I. The condensation of dioxindole with II in the presence of piperidine gave 5-methylisatide, m. 229-30°. Dioxindole does not condense with I. Oxindole combines with II in the presence of piperidine to give 5-methylisatan, m. 195-200° (decomposition). Oxindole gives 7-methylisatan, m. 259°, with I under similar conditions. Oxindole condenses with II in acid solution to form 5-methylisoindigotin. The AcOH solution of the latter heated with Zn gave leuco-5-methylisoindigotin. Similarly, oxindole and I in acid solution gave 7-methylisoindigotin, which gives leuco-7-methylisoindigotin on heating in AcOH with Zn. 5-Methylisoindigotinmonosulfonic acid, m. 310-2° (decomposition), was prepared by treating 5-methylisoindigotin with concentrated H2SO4. 7-Methylisoindigotindisulfonic acid was prepared similarly from 7-methylisoindigotin. It was characterized by its Na, K, Ba and Ag salts. Passing H2S through II and I, resp., in alc. gave 5,5'-(III) and 7,7'-dimethyldisulfisatide (IV). The action of hot alkali on III gave 5,5'-dimethylisoindigotin. Similarly IV gave 7,7'-dimethylisoindigotin. Treating the latter with concentrated H2SO4 gave 7,7'-dimethylisoindigotindisulfonic acid, from which the Na, K, Ba and Ag salts were prepared. Boiling III with pyridine gave leuco-5,5'-dimethylisoindigotin, m. 330°. On heating IV with pyridine, 7,7'-dimethylisoindigotin was obtained and was reduced to its leuco derivative by Zn in boiling AcOH. 5-Methyloxindole, m. 168°, was obtained as a by-product from the pyridine mother liquor from which 5,5'-dimethylisoindigotin had been removed and was identified by giving benzylidene-5-methyloxindole, m. 182°, with BzH. Similarly 7-methyloxindole, m. 203-4°, was obtained from the preparation of 7,7'-dimethylisoindigotin and was identified by giving benzylidene-7-methyloxindole, m. 224°, with BzH. These reactions show that the decomposition of the dimethyldisulfisatides by pyridine is identical with that of disulfisatide. Four isomeric methylindirubins were prepared as follows: (1) 7-methylindol-2-indol-3-indigo by condensing the chloride of I with oxindole; (2) 7-methylindol-3,2-indolindigo by treating I in alc. with indoxylic acid; (3) 5-methylindol-2,3-indolindigo by condensing the chloride of II with oxindole in C6H6; (4) 5-methylindol-3,2-indolindigo by heating II with indoxylic acid in alc. A description of the spectroscopic examination of the methylisoindigotins and methylindirubins is given together with their absorption curves.
IT 871893-79-7P, Isoindigotin, 7-methyl- 871893-80-0P, Isoindigotin, 5,5'-dimethyl-
RL: PREP (Preparation)

L8 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of)
RN 871893-79-7 CAPLUS
CN Isoindigotin, 7-methyl- (2CI) (CA INDEX NAME)



RN 871893-80-0 CAPLUS
CN Isoindigotin, 5,5'-dimethyl- (2CI) (CA INDEX NAME)



L8 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1926:6090 CAPLUS
DOCUMENT NUMBER: 20:6090
ORIGINAL REFERENCE NO.: 20:758e-f
TITLE: Dimethylisoindigotin and a new decomposition of the disulfisatides
AUTHOR(S): Wahl, A.; Faivret, T.
SOURCE: Compt. rend. (1925), 181, 790-2
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB W. and F. on reducing 5-methyl-(I) and 7-methylisatin (II) obtained 5- and 7-methyldioxindole but could not obtain pure 5.methyl- (III) or 7-methyloxindole (IV). A catalytic reduction of isatin and of I gave diisatide and 5,5-dimethylisatide, but II gave no corresponding product. I and II in boiling EtOH with H2S gave non-crystalline 5,5- (V) and 7,7-dimethyldisulfisatide (VI). Treating V and VI with pyridine at 100° gave 5,5-dimethylisoindigotin (its leuco base m. about 330°) and 7,7-dimethylisoindigotin, having a non-crystalline leuco base. From the C5H5N mother liquor was obtained 5-methyloxindole, m. 168°, and 7-methyloxindole, m. 203-40°. Their benzylidine derivs. m. 182° and 224°, resp.
IT 871893-80-0P, Isoindigotin, 5,5'-dimethyl-
RL: PREP (Preparation)
(preparation of)
RN 871893-80-0 CAPLUS
CN Isoindigotin, 5,5'-dimethyl- (2CI) (CA INDEX NAME)



L8 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1926:6089 CAPLUS
DOCUMENT NUMBER: 20:6089
ORIGINAL REFERENCE NO.: 20:758a-e
TITLE: Pyrylium compounds. XVI. Triphenylpyrylium salts containing amino groups
AUTHOR(S): Dilthey, W.; Berres, C.
SOURCE: Journal fuer Praktische Chemie (Leipzig) (1925), 111, 340-52
CODEN: JPCEAO; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C. A. 20, 417. While an NH2 group in the m-position has little or no effect upon the color and behavior of triphenylpyrylium salts, the NH2 group in the p-position acts as an auxochrome. p-AcNHC6H4CH:CHBz and BzMe in a little Ac2O, treated with 3 mols. ZnCl2, give 15% of 4-[4-acetylaminophenyl]-2,6-diphenylpyrylium chloride-zinc chloride, straw-yellow, m. 158°; a solution of EtOH-C6H6N, diluted with hot H2O to turbidity, gives the pale yellow 4-[4-acetylaminophenyl]-2,6-diphenylpyranol, m. 188-9° (dark red melt); perchlorate, orange-yellow, m. 220-5° (decomposition). Concentrated H2SO4 splits off the Ac group, giving with picric acid 4-[4-aminophenyl]-2,6-diphenylpyrylium picrate, violet-black needles with Cu luster, slowly decomps. above 250°; an acid picrate also results, brick-red and transformed by crystallization to the neutral picrate; perchlorate, steel-blue needles, slowly decomps. above 295°. Acetylaminomethoxychalcone, light yellow, m. 186-7°; its solns. show light green fluorescence. With 4-MeOC6H4Ac and ZnCl2, followed by HClO4, there results 4-[4-acetylaminophenyl]-2,6-di-[4-methoxyphenyl]pyrylium perchlorate, orange-red, decomps. above 250°, m. 294° if rapidly heated; picrate, brick-red, m. 267° (decomposition). With 40% HBr, this gives the free amino derivative, as the bromide, violet needles with green surface luster, m. 196°; acid HCl salt, dark brownish red, m. 205° (decomposition). Heating with concentrated HCl 8 h. at 160° gives 4-(4-aminophenyl)-2,6-di-[4-hydroxyphenyl]pyrylium acid chloride, violet-red with a metallic luster, decomps. 240°; perchlorate, reddish yellow needles. 4-[4-Acetylaminophenyl]-2-[4-methoxyphenyl]-6-phenylpyrylium perchlorate, reddish orange, m. 143°. Deacetylation gave the free amino derivative, analyzed as the chloride-HCl, violet-red with green metallic luster, which gives off HCl on heating. Concentrated HCl gives 4-[4-aminophenyl]-2-[4-hydroxyphenyl]-6-phenylpyrylium chloride, violet needles with green luster, decomps. 230°; HCl salt, violet-red, decomps. 240°. 2,4-Di-[4-aminophenyl]-6-phenylpyrylium picrate, violet-black needles, giving a deep red aqueous EtOH solution with marked dyeing capacities.

IT 871893-80-0P, Isoindigotin, 5,5'-dimethyl-
RL: PREP (Preparation)
(preparation of)

RN 871893-80-0 CAPLUS
CN Isoindigotin, 5,5'-dimethyl- (2CI) (CA INDEX NAME)



L8 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L8 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1925:12956 CAPLUS
DOCUMENT NUMBER: 19:12956
ORIGINAL REFERENCE NO.: 19:1706b-d
TITLE: Derivatives of 7-methylisatin
AUTHOR(S): Wahl, A.; Faivret, Th.
SOURCE: Compt. rend. (1925), 180, 580-91
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Oxindole (I) and 7-methylisatin (II) condense in AcOH containing a little HCl to red-brown 7-methylisoindigotin (III), reduced by Zn in AcOH to leuco-III, white needles, m. 310-5°. III dissolves in cold concentrated H2SO4; on heating the disulfonic acid is formed; Na salt, 5H2O, K salt, 3H2O; Ba salt, 6H2O; Ag salt, 0.5H2O. In alc. with a little C5H11N, I and II give 7-methylisatan, white, m. 259° (on hot Hg surface), forming III. With H2S, II in alc. gives dimethyldisulfisatide, changed by warming with alkali to 7,7'-dimethylisoindigotin, too little soluble to purify, but yielding a disulfonic acid (IV); Na salt of IV, 6H2O; K salt, 4H2O; Ba salt, 4H2O; Ag salt, 5H2O. The chloride of II gives with I in C6H6, 7-methylindirubin, obtained by sublimation in vacuo as brown needles with coppery reflex.

IT 861360-24-9P, Indirubin, 7-methyl- 871893-79-7P, Isoindigotin, 7-methyl-
RL: PREP (Preparation)
(preparation of)

RN 861360-24-9 CAPLUS
CN Indirubin, 7-methyl- (2CI) (CA INDEX NAME)



RN 871893-79-7 CAPLUS
CN Isoindigotin, 7-methyl- (2CI) (CA INDEX NAME)



L8 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1925:12955 CAPLUS
DOCUMENT NUMBER: 19:12955
ORIGINAL REFERENCE NO.: 19:1705i,1706a-b
TITLE: An addition product of chlorine and methylchlorohemin
AUTHOR(S): Kuster, William
SOURCE: Z. physiol. Chem. (1924), 141, 291-6
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Methylchlorohemin adds 5 Cl. The vinyl group would account for only 4 of these. The 5th Cl may be removed by boiling with MeOH without replacement by another group. Two more Cl may then be removed by further treatment with MeOH, 1 being replaced by OMe and the other by OH. The original addition product in Et2O loses Cl when treated with NaHCO3 and a mixture of substances containing 3-4 Cl results. When the solid addition product is rubbed with NaHCO3 2 Cl are removed. Since hemin under the same treatment loses the Cl attached to Fe, only 1 of the added Cl should be split off. The question remains whether this is the Cl of the unsatd. position on the nucleus or 1 of the Cl added to the vinyl group. In attempting to prepare a porphyrin by treatment of the addition product with HBr-AcOH only a trace of porphyrin could be demonstrated, while a considerable amount of a crystalline substance of the formula C35H35O6N4FeCl3 was obtained.

IT 871893-79-7P, Isoindigotin, 7-methyl-
RL: PREP (Preparation)
(preparation of)

RN 871893-79-7 CAPLUS
CN Isoindigotin, 7-methyl- (2CI) (CA INDEX NAME)



L8 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1922:24692 CAPLUS
DOCUMENT NUMBER: 16:24692
ORIGINAL REFERENCE NO.: 16:4208e-i,4209a-h
TITLE: N,N-Diphenylindigo
AUTHOR(S): Friedlander, P.; Kunz, K.
SOURCE: Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1922), 55B, 1597-607
CODEN: BDCBAD; ISSN: 0365-9488
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 16:24692
GI For diagram(s), see printed CA Issue.
AB cf. C. A. 6, 2760. o-PhNHC6H4CO2H in the least possible amount of alc. slowly treated with an equal quantity of 30% HCHO and heated 15 min. on the H2O bath gives 93% of N-phenylanthranilic formalide, PhN.C6H4.CO.O.CH2, faintly pink tables from ligroin, m. 89°, which, rubbed with a cold concentrated solution of 0.8 part KCN until dissolved (about 2 hrs.) and made acid to Congo with AcOH or HCl, yields the nitrile HO2CC6H4NPhCH2CN, faintly yellow prismatic crystals from dilute AcOH, m. 133-4°, hydrolyzed by boiling concentrated NaOH to the N-diphenylglycine-o-carboxylic acid (A), faintly yellow prisms from AcOH or MeOH, m. 160-3° (evolution of CO2); the di-Me and di-Et esters are oils. N-4-Chlorophenylanthranilic formalide, similarly prepared, long, almost colorless crystals from ligroin, m. 131-2°, gives the mononitrile, prismatic crystals from dilute AcOH and alc., m. 146-8°, of 4-chloro-N-diphenylglycine-o-carboxylic acid, faintly yellowish crystals from dilute alc., m. 184-6°; the yields in these reactions are 90-5%. A heated 0.5 hr. with an equal weight of dry NaOAc and Ac2O, freed from the excess of Ac2O on the H2O bath, and extracted with H2O gives a yellowish brown resinous mass which, saponified by treating in a little alc. with cold concentrated NaOH to permanent alkaline reaction and filtered into NH4Cl, gives N-phenylindoxyl (B) as a yellow turbidity balling together on shaking to a brown-yellow, somewhat smeary resin, easily soluble in the usual organic solvents with yellow color; it is also obtained in about the same yield (50-60%) from A heated at 190-200° with 2 parts dry NaOH or dry NaOEt; the Me ester of A boiled with NaOEt gives yellowish crystals, m. 114-5°, having the composition of a methyl N-phenylindoxylate; ethyl ester, m. 75-6°. N-4-Chlorophenylindoxyl (C), long yellow prisms from CS2, m. 110-1°. B and C show in general the properties of indoxyl but their reactivity is much less; B forms no indigoid dyes with isatin or isatinanilide; with aromatic aldehydes in the presence of HCl B and C apparently undergo normal condensation to phenylindogenides but only the products obtained with C were crystalline and they were not further investigated. On the other hand, B reacts smoothly with p-ONC6H4NMe2 in alc. in the presence of alkali, giving 1-phenylisatin-2-p-dimethylaminoanil, prismatic crystals from ligroin, m. 173°, soluble in dilute HCl with red-yellow color and repptd. by NaOH but decomps. on boiling into N-phenylisatin (D) and p-H2NC6H4NMe2, does not give phenylindolenaphthaleneindigo with α-naphthol but on warming in Ac2O with 3-hydroxythionaphthene it smoothly yields 2-N-phenyl-indole-2'-thionaphtheneindigo, dark red needles in whose absorption spectrum the maximum of extinction is at λ 535. Heated with CHCl3 and alkali in alc. B gives, like indoxyl, a blue-green color changing to red-violet on acidification. With diazonium compds. B forms azo dyes which have not been investigated; with HCHO and alkali in alc. it condenses to a yellow crystalline substance, reddish yellow prisms from AcOEt, decompose above 190°, become intensely blue-violet, with formation of an easily sol. vat dye, when heated with acids. D, red needles from alc., m. 135-6°, can be obtained directly from B by boiling it in alc. AcOH with solid FeCl3, also, in 4.5 g. yield, from 5 g. E (below) in hot AcOH treated dropwise with dil. HNO3; boiled 0.5 hr. with excess of NaOH it smoothly gives acridine-ms-carboxylic acid; in hot AcOH with 1 equiv. indoxyl and a drop of HCl it condenses to a compd. C22H14O2N2, probably N-phenylindirubin, red-violet needles from AcOH, m. 238°, sol. in cold H2SO4 with dirty green color and forming on heating a SO3H acid sol. in H2O with red color; max. of extinction in the absorption spectrum, λ550. 3-N-Phenylindole-2'-thionaphtheneindigo, similarly obtained from D and 3-hydroxythionaphthene, long red needles from C6H6, sol. in cold H2SO4 with dirty brown color, sulfonated on heating with production of a violet color; max. of extinction, λ 500. N-4-Chlorophenylisat in, from C, yellow needles from alc., m. 197-8°, forms with 3-hydroxythionaphthene a vat dye with a somewhat bluer tinge than the product from D; sodium 4-chlorophenylisatinate, needles easily converted by boiling alkali into 4-chloroacridine-ms-carboxylic acid. N,N'-Diphenylindigo (E), best obtained by oxidation of B in cold faintly alk. soln. with K3Fe(CN)6 (yield, 35-40%, calcd. on the basis of the A used), almost black tables from AcOH or xylene, forms blue-green solns. (red in the higher concns.) with the max. of extinction at λ 630, melts at a high temp. and on higher heating forms a violet vapor, gives with alk. Na2S2O4 a faintly yellow vat dyeing cotton but slightly, wool in dull bluish green shades which have only little fastness; it is strikingly sensitive to hot dil. mineral acids and alkalies; the pure blue-green soln. in AcOH boiled with a drop of dil. HCl becomes a dirty green-brown and H2O gives a flocculent ppt.; it dissolves in cold H2SO4 with green, in fuming acid with blue color with formation of a SO3H acid; a cold alc. soln. is turned a dirty green by a drop of alkali but on dil. or acidification E is repptd. unchanged; on short warming the color changes to brown-yellow and acids ppt. a yellow oil, apparently consisting of N-phenylindoxylaldehyde, for its Et2O soln. gives with HCl a violet color (changed to blue-violet by alkali) and on heating with o-H2NC6H4CO2H and HCl forms a brown-yellow, chrysanilic acid-like product. N,N'-Bis-[4-chlorophenyl]indigo hardly differs from E in shade and properties.
IT 861360-20-5P, Indirubin, 1-phenyl-
RL: PREP (Preparation)
(preparation of)
RN 861360-20-5 CAPLUS
CN Indirubin, 1-phenyl- (2CI) (CA INDEX NAME)



L8 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1921:18577 CAPLUS
DOCUMENT NUMBER: 15:18577
ORIGINAL REFERENCE NO.: 15:3448g-i,3449a-b
TITLE: The action of chloral oxime on the aromatic amines; synthesis of isatins
AUTHOR(S): Martinet, Th.; Coisset, P.
SOURCE: Compt. rend. (1921), 172, 1234-6
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The reaction between CCl3CH:NOH and aromatic amines may follow 2 different courses: (a) in a neutral medium 2 mols. of PhNH2 may take part giving diphenylisonitrosoacetamidine (A), HON:CHC(:NPh)NHPh, (French pat. 291,359 (1899)) while, (b), in a slightly acid medium the product is isonitrosoacetanilide, PhNHCOCH:NOH (B) (French pat. 501-153 (1920)). When B is warmed with H2SO4 it forms isatin. The process requires but 24 hrs. and constitutes a very convenient method for the preparation of ordinary isatin and other known isatins. A new isatin was prepared according to the same method as follows: To 1 mol. of p-chloro-o-anisidine hydrochloride in 1.5 l. of H2O, 1 mol. of NH2OH.HCl was added and the solution brought to boiling; 1 mol. of CCl3CH(OH)2 in 1.3 l. H2O was then added, in small portions at a time, and boiling maintained 5-10 min. longer. By cooling quickly, 2-methoxy-5-chloro-isonitrosoacetanilide, HON:CHCONHC6H3(OMe)Cl (C), separated out, m. 190°, soluble in alc. C gives a violet solution in H2SO4 changing to reddish brown on warming. On heating C with 7 parts of concentrated H2SO4 at 75° for 0.25 hr., cooling and adding an excess of H2O, 4-chloro-7-methoxyisatin (D) precipitated out. It was purified by dissolving in concentrated Na2CO3, filtering and repptg. with HCl. D is insol. in H2O, soluble in AcOH and boiling alc.; it is obtained from the latter as long, red needles, m. 255° on the Maquenne block. The phenylhydrazone, silky, yellow needles, m. 245°; the oxime, m. 230°, is soluble in alc. The isatates can be prepared from D by the action of alc. solns. of the alkalies. Barium isatate was thus obtained, C9H7O4NClBa.H2O, brown plates, soluble in H2O, insol. in alc. The copper isatate was prepared by double decomposition On condensing D with indoxyl, 4-chloro-7-methoxyindirubin (E) resulted, violet needles, slightly soluble in alc. With hyposulfite E gave an unstable, greenish yellow vat which was soon transformed into ordinary indigo.
IT 861326-30-9P, Indirubin, 4-chloro-7-methoxy-
RL: PREP (Preparation)
(preparation of)
RN 861326-30-9 CAPLUS
CN Indirubin, 4-chloro-7-methoxy- (2CI) (CA INDEX NAME)



L8 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1919:15888 CAPLUS
DOCUMENT NUMBER: 13:15888
ORIGINAL REFERENCE NO.: 13:3102g-i,3103a
TITLE: Indirubin
AUTHOR(S): Martinet, J.
SOURCE: Compt. rend. (1919), 169, 183
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Indirubin and some of its homologs have been prepared by three methods, viz.: (1) by the condensation of isatin in alkaline solution with indoxylic acid, in an atmospheric of H2, (2) by the condensation of isatin with the α-anilide of isatin, in (NH4)2S, and (3) by the action of phenylglycine upon isatin in AcOH. The following compds. were prepared: indirubin, 2-indole-3-[1-methylindole]indigo, 2-indole-3-[1-methyl-5-bromoindole]indigo, m. 265-6°, 2-indole-3-[1-ethylindole]indigo, m. 198°, 2-indole-3-[1-ethyl-5-bromoindole]indigo, m. 250-1°, 2-indole-3-[5-methylindole]indigo, m. 289°, 2-indole-3-[5,7-dimethylindole]indigo, m. 337°, 2-indole-3-[1,7-trimethyleneindole]indigo, m. 202°, 2-indole-3-[5-methyl-1,7-trimethyleneindole]indigo, m. 265°, 2-indole-3-[5-methyl-1,7-α-methyltrimethyleneindole]indigo, m. 204-5°. The various physical properties, and dyeing qualities are briefly discussed. These substances dissolve easily in H2SO4, with the formation of their sulfonated derivs., which are direct acid dyes, with colors approaching the mother substances. Despite the differences in mol. wts. of the different compds. the colors are in all cases approximately identical.
IT 861326-22-9P, Indirubin, 5'-methyl- 861326-28-5P, Indirubin, 5',7'-dimethyl-
RL: PREP (Preparation)
(preparation of)
RN 861326-22-9 CAPLUS
CN Indirubin, 5'-methyl- (2CI) (CA INDEX NAME)



RN 861326-28-5 CAPLUS
CN Indirubin, 5',7'-dimethyl- (2CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	159.04	504.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-23.40	-23.40

STN INTERNATIONAL LOGOFF AT 09:52:09 ON 13 JUL 2007

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("7074789").PN.	USPAT; USOCR	OR	OFF	2007/07/13 10:45
L2	1011	514/415.ccls.	USPAT	OR	OFF	2007/07/13 10:45
L3	103	514/415.ccls. and 514/418.ccls.	USPAT	OR	OFF	2007/07/13 10:45
L4	17	514/415.ccls. and 514/418.ccls. and 548/469.ccls.	USPAT	OR	OFF	2007/07/13 10:45
L5	7	514/415.ccls. and 514/418.ccls. and 548/469.ccls. and 548/484.ccls.	USPAT	OR	OFF	2007/07/13 11:09
L6	3	2004/0116388	US-PGPUB; USPAT	OR	OFF	2007/07/13 11:27
L7	1	"7205314"	US-PGPUB; USPAT	OR	OFF	2007/07/13 11:29
L8	1	"6864255"	US-PGPUB; USPAT	OR	OFF	2007/07/13 11:29
S1	14	01/25220	USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/13 10:06
S2	1	02/10158	USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/19 12:22